Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development

Flavin and deazaflavin biosynthesis are highly conserved pathways in mycobacteria, including in Mycobacterium tuberculosis (M.tb). Flavin biosynthesis on one hand is required to produce FMN and FAD, two essential cofactors required to support the flavin intensive lifestyle of mycobacteria. Deazaflavin biosynthesis on the other hand provides F420, an important cofactor used by mycobacteria to curtail antimicrobial and immunological stressors. Given these crucial roles for mycobacterial survival and virulence, these connected pathways have been a recent focus of drug discovery efforts. In addition to providing these important cofactors, studies have shown that the intermediates of this pathway are required to produce metabolic antigens presented by the MHC class I related protein (MR1) molecule in mycobacteria. T cells restricted by the MR1 molecule, which includes Mucosal-associated invariant T cells (MAITs), have also been shown to play a key role during M.tb infection. These findings have made MR1 restricted T cells a prime target for vaccine development. In this review, we focus on what is known about flavin and deazaflavin synthesis pathways in M.tb and other mycobacteria and the distinct features in these species. We also cover the role of these pathways in the physiology of mycobacteria, as well as the status of small molecule inhibitors targeting this pathway. We discuss the current understanding of MR1 immunology in M.tb infection, based on studies in both animal models and humans. Additionally, we highlight recent findings on the diverse repertoire of MR1 T cell receptors that expand during infection and the current status of the MR1 ligandome. Most importantly, we discuss current gaps in understanding the importance of these pathways and explore how this knowledge could drive the development of therapeutics for mycobacterial diseases by targeting these pathways and protective MR1-restricted T cell responses.

1 Introduction

1.1 Mycobacterial diseases: a persistent global health challenge

The Mycobacteria genus comprises over 100 species, with approximately 30 recognized as pathogens causing a spectrum of infectious diseases in mammals (1–4). These pathogens are broadly categorized into three groups: the M.tb complex (MTBC), the Mycobacterium leprae (M. leprae) complex (MLC), and the nontuberculous mycobacteria (NTMs) (1, 3, 5). Together, these groups significantly contribute to the global human health burden, with M.tb and M. leprae being the most impactful. According to the World Health Organization (WHO), M.tb causes tuberculosis (TB)in approximately 11 million people and causes over 1 million deaths annually making it the deadliest infectious disease worldwide (6). M. leprae, though less common, still causes over 200,000 new cases of leprosy each year, a disease that leads to severe disability due to the bacterium’s ability to infect peripheral nerve cells (7). In addition to M.tb and M. leprae, NTMs are emerging as significant pathogens (8, 9). Species such as Mycobacterium avium (M. avium), and Mycobacterium abscessus (M. abscessus) are environmental opportunists (10) that primarily infect individuals with underlying conditions like cystic fibrosis (11, 12), bronchiectasis (13), chronic obstructive pulmonary disease (COPD) (14), or immunodeficiencies (15, 16). However, infections can also occur in immunocompetent individuals (17). The ubiquitous presence of NTMs in the environment makes them difficult to control, and their infections are often underreported due to diagnostic challenges and the absence of systematic global surveillance (10).

The global persistence of mycobacterial diseases is exacerbated by the rise in drug-resistant strains. For M.tb, multi-drug resistance (MDR) remains a significant concern, causing approximately 3% of new TB cases in 2023 (6, 18, 19). Similarly, M. leprae eradication efforts are hindered by the emergence of drug-resistant strains, with around 10% of cases resistant to at least one drug in the standard treatment regimen (20, 21). NTMs present an even greater challenge due to species-specific resistance patterns. For instance, M. abscessus demonstrates resistance to nearly all available antimycobacterial therapies (22–25). The intrinsic resistance mechanisms of NTMs, coupled with their ability to form biofilms (26, 27) that impede drug efficacy, make these infections particularly difficult to treat.

Vaccine development against mycobacterial diseases has seen little success in recent decades. The Bacillus Calmette-Guérin (BCG) vaccine, first introduced in 1921, remains the only approved vaccine for M.tb (28). While BCG provides protection against severe extrapulmonary and meningeal TB in children, it has limited efficacy against adult pulmonary TB, the most prevalent form of the disease (29). This highlights the urgent need for a more effective vaccine. For M. leprae, the absence of a conductive in vitro culture system has hindered the development of attenuated or killed vaccines (30). Similarly, the genetic and pathologic diversity of NTMs poses a barrier to creating a universal vaccine for this group of pathogens. Though BCG offers some cross-protection against leprosy (30) and NTM (31, 32) infections, its efficacy is limited.

The development of effective vaccines and novel antimycobacterial therapies is crucial to achieving the goals of the WHO's End TB Strategy (33) and the Global Leprosy Strategy (34). Addressing the drug resistance crisis and improving diagnostic tools for NTMs are equally important. Advancements in biotechnology, including genomic tools, high-throughput drug screening, and innovative vaccine platforms, hold promise for tackling the persistent challenge of mycobacterial diseases.

1.2 Flavin and deazaflavin biosynthesis as a target for drug discovery and vaccine development

Recent advances in antimycobacterial therapy have led to the approval of bedaquiline, delamanid, and pretomanid for TB treatment by the FDA (35, 36). Bedaquiline, which targets energy metabolism, has reignited interest in targeting bacterial metabolic pathways (37), particularly the central and essential secondary metabolic pathways in mycobacteria. This represents a paradigm shift, as most traditional antitubercular agents primarily target macromolecule synthesis. For instance, isoniazid and ethambutol inhibit the synthesis of the mycobacterial cell wall by targeting mycolic acid (38) and arabinogalactan/lipoarabinomannan (39) biosynthesis, respectively. Rifampicin and rifapentine disrupt transcription by inhibiting RNA polymerase (40), while fluoroquinolones such as moxifloxacin target DNA gyrase (41), an enzyme critical for DNA replication. Pyrazinamide acts by inhibiting the synthesis of coenzyme A, an essential molecule (42). Despite their success, these drugs face challenges such as resistance due to mutations and inactivity against non-replicating persisters (43–45). Consequently, the development of drugs targeting well-characterized and novel pathways remains a priority.

One promising avenue is the flavin biosynthetic pathway (FBP) and the deazaflavin biosynthetic pathway (DBP), both of which are highly conserved in mycobacteria. The FBP synthesizes flavins, including flavin mononucleotide (FMN), and flavin adenine dinucleotide (FAD), which are metabolites that serve as indispensable cofactors for a wide range of enzymatic reactions (46, 47) (Figure 1). DBP synthesizes the deazaflavins 7,8-didemethyl-8-hydroxy-5-deazariboflavin (F0) and F420, metabolites that are involved in a variety of enzymatic reactions (48) (Figure 1). FMN and FAD are derived directly from riboflavin, a vitamin that humans obtain through diet due to the absence of the FBP in eukaryotes. These flavins are critical in mycobacteria because of their unique redox versatility, transitioning between fully oxidized (quinone), one-electron reduced (semiquinone), and two-electron reduced (hydroquinone) states (49). This property renders FMN and FAD irreplaceable by other redox cofactors, such as NAD and NADP (49). The flavin biosynthesis pathway is also upstream of another essential pathway, the vitamin B12 biosynthetic pathway. The reduced form of FMN is used to produce 5,6-dimethylbenzimidazole (DMB) (50), which is the lower axial ligand of vitamin B12, which in turn is a cofactor for several enzymes in M.tb. F0 serves as the precursor for F420, an obligate two-electron carrying deazaflavin essential for oxidative homeostasis in mycobacteria (48). F420 is also necessary for activating the antibiotics delamanid and pretomanid (51), further underscoring its therapeutic importance. Unlike FMN and FAD, which serve as essential cofactors in human metabolism, F0 and F420 and their dependent enzymes are absent in humans (52). The essentiality of FMN, and FAD (46, 53), coupled with the role of F420 in surviving oxidative stress during infection (54, 55), positions the FBP and DBP as quintessential drug targets. Additionally, the absence of both pathways in mammals minimizes the risk of off-target effects, making it an attractive avenue for drug discovery.

Figure 1

Figure 1. Summary of flavin and deazaflavin biosynthetic pathways in mycobacteria. Box 1: Shared pathway showing the synthesis of 5-A-RU. Box 2: Flavin biosynthetic pathway showing synthesis of FMN and FAD. Box 3: Deazaflavin biosynthetic pathway showing synthesis of F420. Blue boxed compounds: molecules known to serve as MR1 agonists or as their precursor. Orange boxed compounds: molecules known to bind MR1 without agonistic properties. (Image created with Biorender.com). GTP, guanosine triphosphate; DARP, 2,5-diamino-6-ribosyl-amino-4(3H)pyrimidinedione 5′-phosphate; DARbP, 2,5-diamino-6-ribityl-amino-4(3H)pyrimidinedione 5′-phosphate; ARPP, 5-amino-6-ribityl-amino-2,4(1H,3H)pyrimidinedione 5′-phosphate; 5-A-RU, 5-amino-6-D-ribitylaminouracil; 3,4-DHBP, 3,4-dihydroxy-2-butanone-4-phosphate; DMRL, 6,7-dimethyl-8-ribityllumazine; FMN, flavin mononucleotide; FAD, flavin adenine dinucleotide; PEP, Phosphoenolpyruvate.

Beyond its metabolic significance, flavin biosynthesis produces specific intermediates presented by the non-classical presenting molecule MHC Class I-Related Protein (MR1) (56, 57). These metabolites are recognized by MR1-restricted T cells (MR1T cells), a unique subset of donor-unrestricted T cells (DURTs). Unlike conventional T cells that recognize peptide antigens, MR1T cells respond to FBP and DBP intermediates through semi-invariant T-cell receptors (TCRs) (57). These MR1T cells can be further subclassified into Mucosal Associated Invariant T (MAIT) cells, which are defined by their expression of the semi-invariant alpha-chain TRAV1-2, and non-TRAV1–2 expressing MR1T cells, which have a more diverse TCR repertoire (58, 59). MAIT cells have been shown to reside in mucosal surfaces (60, 61), including the respiratory tract, the primary infection site of M.tb and several NTMs. Emerging evidence suggests that MAIT cells play a crucial role in controlling mycobacterial infections (62–66) and represent exciting targets for novel therapeutics and vaccines against mycobacteria (67). However, advancing this field requires prioritizing the identification and characterization of the antigenic metabolic produced by mycobacteria.

Historically, the FBP garnered significant attention during the mid-20th century due to its essentiality in bacterial survival (68–74). However, the discovery of alternative drug targets and antimicrobials led to a decline in interest. Moreover, limitations in biotechnological tools at the time hindered deeper exploration of this pathway. With recent technological advances, such as genome editing, high-throughput drug screening, structural biology, and metabolomics, the potential of the FBP as a drug target can now be fully realized. These tools will enable precise investigations into the metabolic capabilities of mycobacteria and the therapeutic exploitation of the FBP.

In this review, we aim to comprehensively describe flavin and deazaflavin biosynthesis and metabolism in mycobacteria, emphasizing its potential as a target for drug discovery and vaccine development. We will highlight existing research gaps that need to be addressed to harness this pathway for therapeutic innovation. Additionally, we will discuss how modern biotechnological tools can accelerate the exploration and exploitation of this vital metabolic pathway.

2 Overview of the flavin and deazaflavin biosynthetic pathway

The study of flavin biosynthesis in mycobacteria dates to the early 1900s, inspired by the striking yellow pigment observed in cultures of M.tb and extracts from M. leprae (68, 70). This observation led to efforts to isolate and characterize the pigment, which was later identified as riboflavin (68). The identification of riboflavin marked a significant milestone in understanding the metabolic capabilities of mycobacteria. Subsequent research explored the relationship between riboflavin production and the environmental conditions under which mycobacteria were grown (69). Investigators sought to determine whether variations in growth conditions influenced riboflavin levels and whether exogenous riboflavin could enhance the growth of the bacilli (69). While these studies provided foundational insights, they yielded inconclusive results regarding the physiological role of riboflavin in mycobacteria. Another avenue of early research focused on the potential connection between riboflavin biosynthesis and virulence. Some studies hypothesized that riboflavin production might contribute to the pathogenicity of mycobacteria, while others examined whether riboflavin deficiency in infected hosts played a role in disease progression (68, 73). Despite these intriguing hypotheses, the limitations of early experimental techniques meant that these questions remained largely unanswered. Although many of these investigations were inconclusive, they laid the groundwork for future research. With the advent of advanced biotechnological tools such as CRISPR-based gene editing, transcriptomics, proteomics, metabolomics, and mass spectrometry imaging, it is now possible to revisit these early questions with greater precision. Modern approaches have started to provide critical insights into the role of riboflavin and deazaflavin biosynthesis in mycobacteria and its potential connections to virulence, host-pathogen interactions, and metabolic adaptability. Revisiting these early studies in the context of contemporary science could uncover novel aspects of mycobacteria biology with implications for therapeutic strategies.

The discovery that mycobacteria could produce F0 and F420 was made relatively recently (48, 75). The initial discovery of F0 and F420 biosynthesis was made in archaeal methanogens (76). However, due to the estranged nature of the archaeal genome compared to other domains, no connection was made to the synthesis of F0 and F420 in bacteria (77, 78). In the early 1980s, F0 was isolated from M. avium (79) and later discovered in other members of the mycobacterial genus (48). Interestingly, the evolutionary origin of F0 and F420 was eventually tied to Actinobacteria (80), a phylum to which the mycobacteria genus belongs. The evolutionary conservation in this phylum therefore highlights the physiological importance of these compounds. Although the biosynthesis of F0 and F420 is not essential for viability (81), evidence suggests that they play a role in redox homeostasis and detoxification of environmental stressors in mycobacteria (54, 82–84).

Genetic manipulation experiments including gene knockdown, gene knockout, and complementation studies have provided insight into the importance of these pathways (46, 54, 83). Additionally, since the discovery of these pathways in mycobacteria, it has also become apparent that the final product of this pathway is not limited to the currently known catalog of molecules (85–87). In the next section, we cover the enzymes required for flavin and deazaflavin biosynthesis, the genetic architecture of the pathway, its uniqueness in comparison to other flavin and deazaflavin-producing microorganisms, and production of tangential metabolites.

2.1 Core enzymes and reactions

The FBP and DBP together consist of nine enzymes (Figures 1, 2). Three of these enzymes (RibA2, RibG and an uncharacterized phosphatase) are shared between the two routes (88–90). These shared enzymes are required for the conversion of guanosine triphosphate (GTP) to 5-Amino-6-(ribityl-amino) uracil (5-A-RU) (88). Subsequently, 5-A-RU is converted into riboflavin by the two enzymes, RibH and RibC and eventually FMN and FAD by RibF (47). Alternatively, for the synthesis of F0 and F420, four enzymes are required, namely FbiA, FbiB, FbiC and FbiD to which 5-A-RU serves as the starting material (91–93). Here, we go over the core enzymes of this pathway and the similarity and differences to well characterized organisms such as Bacillus subtilis (B. subtilis) and Escherichia coli (E. coli). Biochemical characterization of these pathways is beyond the scope of this review, but has recently been reviewed elsewhere (94, 95).

Figure 2

Figure 2. Genetic architecture of flavin and deazaflavin biosynthetic genes in mycobacteria. Genes are color coded according to enzymes in Figure 1. Genes in brackets are experimentally confirmed (*) or hypothesized (#) to be operonic. (Image created with Biorender.com).

2.1.1 FBP and DBP shared pathway

The first step in flavin biosynthesis is catalyzed by the bifunctional RibA2 enzyme (GTP cyclohydrolase II/DHBP synthase). RibA2 catalyzes the hydrolytic release of a carbon and pyrophosphate from GTP to form 5-amino-6-ribosylyamino-4(3H)-pyrimidinone 5`-phopshate (47). RibG, another bifunctional enzyme, firstly deaminates the pyrimidine ring and then reduces the ribosyl side chain of the product of RibA2 to form 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione 5`-phosphate (47). The product of RibG is then dephosphorylated to form 5-amino-6-D-ribitylaminouracil (5-A-RU). The phosphatase responsible for the dephosphorylation step is unknown but it is hypothesized to be catalyzed by a phosphatase with low substrate specificity (96). 5-A-RU then serves as the common substrate for the synthesis of both flavins and deazaflavins.

2.1.2 Riboflavin biosynthesis

For flavin synthesis, the first step involves the condensation of 5-A-RU with 3,4-dihydroxy-2-butanone 4-phosphate (3,4-DHBP) by RibH, a lumazine synthase, to form 6,7-dimethyl-8-ribityllumazine (DMRL). 3,4-DHBP is formed from ribulose 5-phosphate by RibA2 via a dismutase reaction (97). Although, the condensation of 5-A-RU and 3,4-DHBP to form DMRL can occur non-enzymatically in an aqueous solvent, it has been shown that RibH is required for DMRL synthesis in mycobacteria (46). In the final step, RibC (riboflavin synthase) condenses two molecules of DMRL to form one molecule of riboflavin and one molecule of 5-A-RU (88). RibF, a bifunctional enzyme, first phosphorylates riboflavin to form FMN which it then converts to FAD (88).

2.1.3 Deazaflavin biosynthesis

The synthesis of F0 involves the condensation of 5-A-RU with tyrosine. This reaction is catalyzed by a two-domain fusion protein FbiC (F0 synthase) (98). The synthesis of F420 from F0 requires both phosphoenolpyruvate (PEP) and GTP. PEP is guanylylated by FbiD (93), a guanylyltransferase to form enolpyruvyl-diphospho-5′-guanosine (EPPG). The transferase FbiA then transfers PEP to F0 to form dehydro F-420-0 (91). FbiB, a two-domain protein, reduces dehydro-F-420–0 via its reductase domain to afford F-420-0 (91). An oligoglutamate tail is then added to F-420–0 by FbiB via its γ-glutamyl ligase domain (99, 100). The oligoglutamate tail has been shown to contain between five to seven glutamate residues in mycobacteria (48).

2.2 Genetic architecture and uniqueness of the FBP in mycobacteria

The FBP and DBP are highly conserved across Mycobacteria, as illustrated in Figure 2. In M.tb and Mycolicibacterium smegmatis (M.smeg), three key genes of this pathway—ribC, ribA2, and ribH—are organized in an operon known as the rib operon (46). The ribG gene is located separately from the operon with two intervening open reading frames (ORFs) and appears to have no transcriptional relationship with the rib operon (46). Additionally, ribF is expressed as a standalone gene, situated distally from the other pathway genes. In some mycobacterial species, two ORFs that are not involved in riboflavin biosynthesis are found embedded within the rib operon. The high degree of synteny in the arrangement of these operonic genes across different mycobacterial species suggests that they may also be expressed as an operon in other members of this genus. This operonic arrangement of riboflavin biosynthesis genes are a common feature in eubacteria. For example, in B. subtilis, all the genes of the riboflavin biosynthetic pathway (RBP) are clustered in a single operon regulated by a FMN riboswitch (101). The FMN riboswitch serves as a negative feedback regulatory mechanism to prevent the excess production of riboflavin due to the high energy cost of this process and to ensure redox homeostasis (102). A similar mechanism exists in E. coli, despite the genes being scattered across its genome (102). Bioinformatic studies have suggested that mycobacteria lacks a FMN riboswitch regulating the RBP (103), which may indicate that there are other mechanism(s) in place to mitigate the problem of excess riboflavin. One such mechanism could be flavin sequestering proteins that is highly conserved in mycobacteria, which will be discussed later in this review (104, 105). Another reported mechanism is the redox homeostatic system (RHOCS) made up of protein kinase G (PknG), ribosomal protein L13 and RenU, a Nudix hydrolase. The disruption of the RHOCS prevents the degradation of FAD and NAD(P)H by RenU, leading to their accumulation (106). However, the RHOCS is not specific for alleviating redox stress due to flavins as this system primarily senses high levels of NADH. It is also probable that the basal rate of riboflavin biosynthesis provides the right quantity of cofactors (FMN and FAD) needed to drive the high flavin dependence of mycobacteria (107).

A common feature of the RBP in bacteria is the presence of redundant systems to ensure sufficient riboflavin supply. These mechanisms include duplicate pathway genes, which may afford protection from inhibitory molecules targeting riboflavin biosynthesis (108), as well as the ability of some pathogenic bacteria to also encode a riboflavin uptake mechanism (109). The presence of redundant supplies of riboflavin has been shown to be important in the colonization of the host by certain pathogens with the dependence on exogenous or endogenous source of riboflavin varying based on environmental conditions (108). Bioinformatic annotation of the M.tb genome indicate the presence of two ribA genes, rv1940 and rv1415, as well as a second putative deaminase, rv2671 (110). However, functional studies confirmed that only rv1415 encodes a functional enzyme (46), and that rv2671 encodes a dihydrofolate reductase (DHFR) rather than a deaminase (111), thus indicating the presence of a sole gene for all the steps of this pathway. Conversely, in the non-pathogenic M.smeg, a redundant gene encoding a lumazine synthase (RibH) was observed (46). In terms of riboflavin uptake mechanisms, of the nine different families of riboflavin importers, none has been bioinformatically observed in mycobacteria (112).

The lack of redundancy of riboflavin supply and dependence on a sole ORF for each step of riboflavin biosynthesis in pathogenic mycobacteria suggests that targeting this pathway for therapeutics should be relatively straightforward. Additionally, distinct features of the mycobacterial RBP could be leveraged to develop targeted therapeutics that selectively inhibit mycobacteria while sparing the host microbiome. One major concern with antimicrobial therapies is the unintended disruption of commensal bacteria, which can have significant health consequences. However, structural and functional differences in the mycobacterial RBP compared to other bacteria present an opportunity to design highly specific inhibitors. In some riboflavin-competent organisms, the function of hydrolyzing the GTP ring and synthesizing 3,4-dihydroxy-2-butanone-4-phosphate (DHBP) is carried out by two separate enzymes, RibA and RibB (108, 113), whereas in mycobacteria, this process is consolidated into a single multifunctional enzyme (114). These distinctions could serve as a basis for designing inhibitors that exploit the structural and mechanistic uniqueness of mycobacterial riboflavin biosynthesis while avoiding off-target effects on beneficial microbiota which is a strategy currently employed by bedaquiline, an antimicrobial that specifically targets the mycobacterial ATP synthase. By targeting these species-specific variations in flavin biosynthesis, it may be possible to develop antimycobacterial agents that effectively combat infections without the collateral damage associated with broad-spectrum antibiotics. This approach underscores the importance of detailed biochemical and structural characterization of the mycobacterial RBP for the development of therapeutics.

Given the essentiality of flavin biosynthesis and the flavin intense lifestyle of mycobacteria, it is intriguing that pathogenic mycobacterial species do not encode redundant mechanisms to ensure the supply of these vital molecules (46, 107, 115). This phenomenon can likely be attributed to the absence of evolutionary pressure to develop redundancy. Pathogenic mycobacteria colonize traditionally sterile anatomical sites, such as the lungs or peripheral nerves, where they encounter minimal microbial competition. This sterility reduces the likelihood of exposure to inhibitory molecules or metabolic competition from other bacteria, thereby diminishing the selective pressure to evolve backup systems for flavin production. By contrast, environmental mycobacteria and other bacteria that coexist in competitive ecosystems are often subjected to such pressures, which may drive the evolution of metabolic redundancy or alternative pathways to ensure survival (10). For example, photolumazines, which have only been observed in M.smeg, can serve as inhibitors of riboflavin synthase which may provide an advantage in the midst of other environmental microorganisms (116). This distinction emphasizes the unique metabolic adaptations of pathogenic mycobacteria, shaped by their specialized niches within the host, and further highlights flavin biosynthesis as a vulnerable and attractive target for therapeutic development.

2.3 Genetic architecture and uniqueness of the DBP in mycobacteria

Interestingly, the initial genome annotation of M.tb in 1998 did not include genes required for deazaflavin biosynthesis (110). In 2001, fbiA and fbiB were identified as essential for F420 biosynthesis in Mycobacterium bovis (M. bovis) through PA-824 (now pretomanid)-induced selection of transposon mutants (117). The same group later identified fbiC using a similar approach (92), and the discovery of fbiD followed, linked to mutations in its ORF that conferred resistance to pretomanid and delamanid (93). Like the rib operon, two of the fbi genes, fbiA and fbiB, are juxtaposed and have been shown to be co-transcribed (118), while fbiC and fbiD are located at separate loci (Figure 2). Intriguingly, the genetic architecture of the deazaflavin pathway in mycobacteria differs from the archaeal pathway. Five genes instead of four are required for F420 synthesis in archaebacteria with the role of fbiC requiring two separate genes cofG and cofH (89). Also, the length of the polyglutamate tail of F420 has been shown to be shorter in the archaeal organisms in comparison to mycobacteria (90, 119). The distinct mechanisms through which different organisms are able to regulate the length of the glutamate tail is yet to be elucidated. The length of the polyglutamate tail has been shown to impact the kinetics, the turnover rate, and the interaction of F420 with oxidoreductases (120). Shorter tail length has also been linked to resistance (121), however, whether mycobacteria can vary the tail length depending on environmental conditions has yet to be fully understood.

Initial studies characterizing deazaflavin biosynthesis had shown that L-Lactyl-2-diphospho-5`-guanosine (LPPG), a metabolite made from the guanylylation of 2-Phospho-L-lactate via FbiD, was required for the synthesis of F420 (122, 123). However, a study by Bashiri et al. showed that PEP rather than LPPG was required for F420 biosynthesis in mycobacteria (99). This clarification of the substrate of FbiD was due to the lack of genetic and biochemical evidence supporting the synthesis of 2-Phospho-L-lactate in mycobacteria, while PEP was a well characterized product of the glycolytic pathway. This discovery challenged the long-standing schema of this pathway. Recently, the diverse nature of this pathway has become more obvious, with different organisms using molecules other than PEP for F0 synthesis (89). For example, the Gram-negative bacterium Paraburkholderia rhizoxinica utilizes 3-phopsho-D-glycerate (3PG) instead of LPPG or PEP (124). The use of PEP rather that LPPG in mycobacteria was further supported by the presence of a FMN binding domain in FbiC which catalyzes the reduction of dehydro-F420-0 (99), the product of FbiA if PEP is used. Also, the synthesis of F0 was thought to require the condensation of 5-A-RU and 4-hydroxyphenylpyruvate (4-HPP). However, the biochemical characterization of FbiC enabled better elucidation of F0 synthesis and demonstrated the need for tyrosine instead of 4-HPP.

2.4 Tangential pathways beyond the FBP and DBP

Beyond the production of flavins and deazaflavins, 5-A-RU may participate in the synthesis of additional metabolites. Notably, 5-A-RU condenses non-enzymatically with glyoxal and methylglyoxal, secondary products of metabolism, to form 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) (125). These unstable metabolites are potent ligands for MR1. Additionally, other studies have demonstrated the formation of lumazine compounds through the non-enzymatic condensation of 5-A-RU with transamination products (126, 127). The enzymatic modification of 5-A-RU to provide starting material for a tangential metabolic pathway has also been observed in other organisms (128). The promiscuity of 5-A-RU and the non-enzymatic production of its derivatives suggest that this pathway may contribute to the synthesis of other metabolic products. Although most known products of 5-A-RU outside flavins and deazaflavins have only been characterized as MR1 antigens, it is necessary to determine whether these metabolites have other physiological roles in mycobacteria. In addition, the distinct metabolome of mycobacteria (129, 130) compared to other organisms may provide an avenue for the formation of novel secondary metabolites derived from 5-A-RU.

Another point in the FBP that may lead to the synthesis of other novel metabolites is from DMRL. DMRL, the direct precursor for riboflavin, belongs to the broad class of nitrogen-containing heterocycles known as pteridines or lumazines. The ribityl lumazine motif serves as a core structure for several naturally occurring compounds in various bacterial species, often carrying diverse additional moieties that contribute to their biological functions. One notable class, photolumazines, has been shown to be produced by M.smeg (85, 86), and is yet to be observed in any pathogenic species. Photolumazines may play a role in protecting M.smeg in light-exposed environments as these compounds function in association with lumazine binding proteins as optical transponders (131). Therefore, the presence of photolumazines and their functional role in pathogenic mycobacteria such as M.tb and M. leprae is likely minimal or absent, given their evolution to survive in the absence of light. However, NTMs, often sourced from environmental niches (10), may produce photolumazines. Since both DMRL and 5-A-RU have been implicated in the formation of lumazines in other organisms, it is critical to investigate pathogenic mycobacteria for the presence of such substrates and to explore their potential physiological and immunological relevance.

FBP also provides a precursor essential for cobalamin biosynthesis. Specifically, reduced flavin mononucleotide (FMN-H₂) undergoes reduction by BluB, a nitroreductase-like enzyme, yielding DMB and erythrose-4-phosphate (E4P) (50). Subsequently, DMB is incorporated into cobalamin through additional enzymatic reactions (50). While cobalamin is critical for mycobacterial metabolism, members of the MTBC typically obtain it exogenously from their host due to an incomplete de novo synthesis pathway (132, 133). In contrast, NTMs possess the complete machinery to synthesize cobalamin independently (132), relying on DMB derived from FMN. The broader implications of disrupting the synthesis of cobalamin lie beyond the scope of this review but have been previously addressed elsewhere (134).

With the wealth of information now available about these pathways and the expanding repertoire of therapeutic strategies beyond traditional small-molecule inhibitors, there is significant potential to develop novel antimycobacterial agents. Additionally, the conservation of flavin and deazaflavin biosynthesis among mycobacteria suggests that inhibitors designed to target this pathway in one species will likely be effective against others. For example, bedaquilline targets ATP synthase, a highly conserved function in mycobacteria, and has demonstrated potent antibacterial activity against several mycobacterial species (135–137). This broad applicability enhances the feasibility of developing a single therapeutic agent capable of targeting multiple pathogenic mycobacteria, making flavin and deazaflavin biosynthesis an attractive target for the next generation of antimycobacterial drugs.

3 Flavin biosynthesis as a target for drug discovery

At the time of the discovery of riboflavin production in mycobacteria, there was significant interest in identifying metabolites essential for the growth of pathogens (74). The prevailing assumption was that structural analogs of these metabolites could serve as starting points for antimicrobial development, an approach inspired by the success of prontosil, a dihydropteroate synthase inhibitor (138, 139), as an antibacterial agent. However, because riboflavin is utilized by both prokaryotic and eukaryotic organisms, the strategy of modifying riboflavin for antimicrobial purposes had to be approached with caution. While the absence of the flavin and deazaflavin biosynthetic pathway in humans makes its intermediate steps promising targets for drug discovery, no successful clinical antimicrobial agents have been developed to disrupt this pathway to date.

The supply of riboflavin, essential for the synthesis of FMN and FAD, is indispensable for both eukaryotic and prokaryotic organisms (140). The ability of the alloxazine ring to maintain a quinone, semi-quinone and fully reduced state makes its utility as a cofactor unique (49). In mycobacteria, the extensive presence of flavoproteins suggests a flavin-intensive metabolic lifestyle (107). The functional roles of these flavoproteins span critical cellular processes such as fatty acid metabolism, cholesterol metabolism, nucleotide biosynthesis, and redox homeostasis (Figure 3). Major components of the electron transport chain (ETC) either contain flavoproteins or directly utilize FAD/FMN as cofactors. These include NADH dehydrogenase-1 (NDH-1) (141), a multi-subunit enzyme complex, NDH-2 (142), a single-polypeptide enzyme, and succinate dehydrogenase (SDH) (143).

Figure 3

Figure 3. Gene ontology enrichment analysis for flavin and deazaflavin dependent proteins in mycobacteria. Flavin-dependent (A) and deazaflavin-dependent (B) proteins in mycobacterial species were identified from the UniProtKB database based on their annotation as an FMN, FAD or F420 dependent/binding protein. Gene Ontology (GO) enrichment analysis was conducted with ShinyGO (v0.82) (154), using all available proteins pulled from UniProtKB as described. Statistical significance was determined using a false discovery rate (FDR) threshold of 0.05 to correct for multiple hypothesis testing. Fold enrichment was calculated as the ratio of observed to expected gene counts in each GO term, indicating the degree of overrepresentation. Enriched GO terms were manually reviewed and grouped into broader functional categories to facilitate interpretation of biological themes.

F420, although dispensable for viability, plays a crucial role in mycobacterial physiology (89, 99). The loss of F420 biosynthesis may not alter viability but has been shown to negatively impact the fitness of mycobacteria (75, 82–84, 144), indicating the lack of compensatory mechanisms for this loss. Unlike FMN and FAD, F420 is an obligate two-electron carrier with a low redox potential similar to NAD(P)H (89, 90). Its precursor, F0, appears to serve solely as an intermediate in F420 biosynthesis in mycobacteria. Genes required for F420 synthesis have been identified in most clinically relevant mycobacteria. Of particular interest is the conservation of F420 biosynthesis in M. leprae (48), a species that has undergone extreme genome reduction. This suggests that F420 is functionally significant despite the minimal genetic repertoire of M. leprae. Additionally, bioinformatic analyses have revealed numerous F420-dependent genes in mycobacteria (82, 145), and biochemical characterization has confirmed the F420 dependency of several protein products (146–148). These enzymes participate in key physiological processes, including cell wall biosynthesis (148), respiration (149), redox homeostasis (84, 149, 150), and the degradation or inactivation of antimicrobials and intoxicants (151, 152). Some of these functions have been inferred from genetic disruption of F420 biosynthesis (83, 93, 117, 148, 152), yet the primary proteins responsible for these roles remain unidentified. Identifying these primary players will provide deeper insight into their role in the virulence of pathogenic mycobacteria and inform the development of strategies to directly inhibit or circumvent these mechanisms, thereby enhancing both immunological and antimicrobial clearance.

Although the catalog of characterized flavoproteins and deazaflavoproteins in mycobacteria has expanded in recent years (Figure 3), there remains a significant gap in our understanding of the role of these groups of proteins. The M.tb genome is predicted to encode approximately 150 flavoproteins and 33 deazaflavoproteins with similar numbers expected in other mycobacterial species (82, 107). However, only a subset of these flavoproteins and deazaflavoproteins have been experimentally characterized. Comprehensive characterization of these proteins and their functional roles is essential for understanding some of the core metabolic processes required for mycobacterial survival. With advancements in bioinformatics and biochemical affinity techniques such as click chemistry, we now have the tools to facilitate this characterization. Since both riboflavin and F0 can be taken up passively (46, 90), these approaches offer a promising path toward uncovering novel therapeutic targets in mycobacteria.

3.1 Physiological roles of flavins and deazaflavins in mycobacteria

There are currently over 200 families of enzymes that depend on FMN or FAD as cofactors (153) and 8 families that depend on deazaflavins (90). These proteins are involved in a plethora of functions in nature and in the mycobacteria species. We have highlighted some of these functions in mycobacteria in Figure 3.

In this section, we provide an overview of the function of key flavin dependent enzymes, flavoproteome, and deazaflavin dependent enzymes in the context of features essential to the pathogenicity of mycobacteria.

3.1.1 Energy metabolism/respiration

ATP production is essential for the viability of mycobacteria (155–157), and to ensure a continuous supply of energy under diverse environmental and chemical stressors, the bacterium has evolved a robust ATP-generating system based on oxidative phosphorylation. While some components of the ETC are functionally redundant and can be substituted, others are indispensable (158–160). Key entry points into the ETC (161),including the NDH-1, NDH-2, and SDH, require FAD as a cofactor. The essentiality of the two NADH dehydrogenases is underscored by the inability to generate a double mutant lacking both enzymes (162). Given the flavin dependence of these critical enzymes, disruption of flavin biosynthesis is expected to impair ETC function and compromise ATP production. Additional ETC-linked enzymes such as malate:quinone oxidoreductase (Mqo) (163, 164), proline dehydrogenase (Pru) (165, 166), and lipoamide dehydrogenase (Lpd) (167, 168), also require flavin cofactors, further underscoring the centrality of flavin metabolism. Consequently, even alternative electron entry routes that might compensate for the loss of NDH function are likely to be non-functional in the absence of flavins.

In addition to canonical flavin-dependent pathways, mycobacteria may utilize deazaflavin, F420, as an electron carrier. The deazaflavin-dependent nitroreductase (Ddn) (149), a peripheral membrane protein known for activating the prodrug pretomanid (169), has been shown to reduce menaquinone and is required under hypoxic conditions. The genome of M.tb encodes two additional homologs, Rv1261c and Rv1558, which exhibit enzymatic activities similar to Ddn and may similarly contribute to menaquinone reduction (149). However, unlike the flavin-dependent ETC components, the roles of these F420-dependent quinone reductases in electron transport remain to be fully elucidated and warrant further investigation.

3.1.2 Redox homeostasis

Redox homeostasis is the ability of living systems to maintain a balance between oxidative and reductive species, ensuring a non-toxic intracellular environment. Since fundamental biological processes inherently impact an organism's redox status, redox homeostasis is essential for survival. This is particularly critical for pathogenic mycobacteria, which encounter oxidative and nitrosative stress in the form of reactive oxygen species (ROS) and reactive nitrogen species (RNS) within the macrophage phagosome during infection. To counteract these host-imposed stressors, mycobacteria have evolved multiple strategies, including the use of flavin and deazaflavin redox couples (FAD/FADH₂, FMN/FMNH₂, and F420/F420-H₂) (89, 170).

FMN and FAD serve as cofactors for various proteins involved in redox homeostasis. A prime example is their role in recycling thiol-based redox buffers in mycobacteria (171). Mycothiol (MSH), a low-molecular-weight thiol unique to mycobacteria, functions as a redox buffer by neutralizing oxidative stress (172). During this process, MSH is oxidized to mycothiol disulfide (mycothione, MSSM), concomitantly reducing ROS. The flavoprotein mycothiol disulfide reductase (Mdr) catalyzes the conversion of MSSM back to its reduced form, MSH, restoring the redox buffer capacity (170). Loss of Mdr impairs bacterial growth and increases sensitivity to oxidative stressors, whereas its overexpression enhances resistance to oxidative stress. Another flavoprotein, ThyX, a thymidylate synthase (173), has also been implicated in oxidative stress protection in mycobacteria (174), although the precise mechanism is yet to be elucidated. Lipoamide dehydrogenase, Lpd, a flavoprotein is part of the peroxynitrite reductase/peroxidase (PNR/P) complex, a system involved in the detoxification of RNIs during infection (175). TyzC, a flavin-dependent oxidase (FDO) of the nitroreductase (NTR) superfamily has also been implicated in redox homeostasis as a transposon mutant of tyzC exhibited increased sensitivity to oxidative stress (176).

The deazaflavin cofactor F420 also plays a crucial role in mycobacterial redox homeostasis. Initial studies demonstrated that F420-deficient mutants exhibit heightened sensitivity to oxidative stress, later attributed to the requirement of reduced F420 (F420-H₂) for oxidative stress resistance (83, 149, 150). The reduction of F420 is catalyzed by an F420-dependent glucose-6-phosphate dehydrogenase (Fgd), which links glucose-6-phosphate (G6P) metabolism to oxidative stress responses (146, 150). The loss of Fgd results in increased sensitivity to oxidative stress, further underscoring its importance in redox homeostasis (177). Interestingly, M. leprae encodes Fgd as its sole glucose-6-phosphate dehydrogenase (150), although whether it plays a similar role in redox homeostasis in this species remains unknown. Fgd is also present in other mycobacteria, including NTMs (150), but its contribution to redox homeostasis across species requires further investigation. Interestingly, the preference for Fgd over the more common NADP-dependent glucose-6-phosphate dehydrogenase in mycobacteria under oxidative stress conditions has not been elucidated. Understanding this preferential utilization could provide deeper insights into how mycobacteria orchestrate their metabolic and redox responses during host infection.

3.1.3 Central carbon metabolism

Central carbon metabolism in mycobacteria plays a vital role in energy generation and the provision of precursors required for the synthesis of essential macromolecules such as DNA, RNA, lipids, and amino acids. The core central carbon metabolism network consists of the Embden–Meyerhof–Parnas pathway, the pentose phosphate pathway (PPP), and the tricarboxylic acid cycle (TCA) (178). Additionally, mycobacteria encode supplementary pathways such as the glyoxylate shunt and the methylcitrate cycle (178, 179), which enable metabolic adaptation under nutrient-limited or hostile conditions. While the bacilli is capable of extensive remodeling of these pathways by switching entirely to supplementary routes or bifurcating metabolic flux depending on environmental and nutritional cues, certain core enzymatic functions remain essential (179, 180). Several of these enzymes require flavin or deazaflavin cofactors for their activity. SDH (181), which bridges the TCA cycle and the ETC, catalyzes the oxidation of succinate to fumarate using FAD as an electron carrier. Similarly, Lpd (168), a flavoprotein within the pyruvate dehydrogenase complex of the EMP pathway, facilitates the conversion of pyruvate to acetyl-CoA, a central intermediate of the TCA cycle (182). While Fgd is primarily linked to redox homeostasis through the generation of reduced F420-H₂ (177), its activity may also influence central carbon flux. Specifically, the upregulation of Fgd during oxidative stress suggests a potential shift in metabolism favoring the PPP, which is a major source of NADPH for detoxification processes. However, the mechanistic basis for this metabolic reprogramming and its regulation in response to oxidative cues remains to be fully elucidated.

Lactate serves as an alternative carbon source for mycobacteria, particularly within the host environment, where infected macrophages shift their metabolism toward aerobic glycolysis (183). This host metabolic reprogramming results in elevated lactate levels, which mycobacteria can exploit. The bacilli encodes two lactate dehydrogenases, LldD1 and LldD2 (184). Of these, LldD2, a flavin-dependent enzyme, is functionally active in oxidizing lactate to pyruvate (184). The resulting pyruvate can enter the TCA cycle or serve as a substrate for gluconeogenesis via a phosphoenolpyruvate carboxykinase (PckA)-dependent pathway (178). Importantly, LldD2 is essential for intracellular survival, as its deletion leads to impaired growth within macrophages (183). Furthermore, LldD2 has been identified as a target of evolutionary pressure; mutations within its ORF have been associated with increased expression (184), highlighting its role as a key metabolic enzyme and potential driver of virulence in mycobacteria.

3.1.4 Fatty acid and cholesterol metabolism

The metabolism of fatty acids (FAs) and cholesterol is a cornerstone of mycobacterial survival and immunomodulation during infection (185, 186). Within macrophages, the bacterium efficiently utilizes host-derived fatty acids and cholesterol as primary carbon sources (186). In addition to catabolizing these lipids, mycobacteria synthesizes a variety of lipid species and lipid-containing molecules that contribute to the unique physicochemical properties of its cell wall and function as virulence factors through interactions with host immune components (187, 188). Flavoproteins and deazaflavoproteins are essential to both the catabolism of host lipids and the anabolism of cell wall-associated fatty acids. The β-oxidation of fatty acids and cholesterol yields acetyl-CoA and propionyl-CoA, which feed into the TCA cycle and gluconeogenesis, supporting both energy production and biosynthetic needs (186). Mycobacteria encode a large number of FAD-dependent acyl-CoA dehydrogenases (ACADs) involved in the β-oxidation of fatty acids (189). These enzymes function in concert with the electron transfer flavoprotein (ETF) system, composed of FixA, FixB, EtfA, EtfB, and EtfD (189, 190). Among these, EtfA and EtfB are flavoproteins that mediate the transfer of electrons from ACADs to the menaquinone pool in the ETC (189). For cholesterol degradation, mycobacteria express several flavin-dependent dehydrogenases, including ChsE3, HsaA, HsaB, KshB, LpdC, FadE30, LpdA, and LpdB and an F420-dependent oxidoreductase (Rv3520c). These enzymes play critical roles in the sequential breakdown of the cholesterol side chain and ring structures, facilitating the assimilation of cholesterol-derived carbon (186).

Flavins and deazaflavins also play a role in the biosynthesis of fatty acids and complex lipids that constitute the lipid-rich cell wall of mycobacteria. The bacterium encodes a multifunctional type I fatty acid synthase (FAS-I), responsible for the de novo synthesis of fatty acids ranging from C_16/C18 to C_24/C26 (191). These products are either incorporated into basic membrane phospholipids or funneled into the type II fatty acid synthase (FAS-II) system for the synthesis of mycolic acids, essential components of the mycobacterial cell envelope (192). The enoyl-ACP reductase component of FAS-I, which catalyzes the final and rate-limiting step of fatty acid chain elongation, is FMN-dependent (191), making it a key flavoprotein in lipid biosynthesis. Several complex lipids with defined roles in virulence also require flavin or deazaflavin cofactors for their synthesis. Phthiocerol dimycocerosates (PDIMs) are apolar lipids located in the outermost layer of the mycobacterial cell wall and function as major virulence factors by promoting phagosomal escape and inhibition of autophagy (193, 194). The biosynthesis of PDIM depends on phthiodiolone ketoreductase (fPKR), an F420 H₂-dependent enzyme (195). Mutants deficient in PDIM synthesis are significantly attenuated in virulence, demonstrating the importance of this pathway in immune evasion (193, 194). Similarly, ketomycolic acids, which contribute to pellicle formation and drug tolerance, are synthesized from hydroxymycolic acids via an F420-dependent dehydrogenase (196). More recently, the production of acyl-tyrazolone (acyl-Tyz), a tyrosine-derived lipid, has been observed in mycobacteria (197). This compound is synthesized by a flavin-dependent nitroreductase-like enzyme, although its precise function and relevance to virulence are still under investigation (197). Collectively, these findings underscore the essential role of flavoproteins and deazaflavoproteins in the biosynthesis of key lipid-based virulence determinants in mycobacteria. Targeting flavin biosynthesis may not only compromise cell wall integrity but also increase cell wall permeability, potentially enhancing the efficacy of other antimicrobials that are otherwise impeded by the bacteria’s lipid-rich barrier.

3.1.5 Drug resistance/detoxification

The detoxification of xenobiotic compounds significantly enhances the survival and resilience of mycobacteria. To neutralize antimicrobial agents, mycobacteria utilize specialized enzymes such as nitroreductases and monooxygenases. The flavin-dependent monooxygenase MabtetX in M. abscessus efficiently inactivates tetracycline and doxycycline, illustrating a critical drug resistance mechanism dependent on flavins (198). Another example is the flavin-dependent nitroreductase NfnB, conferring resistance to BTZ-043 in M. smeg (199). Although direct homologs of MabtetX and NfnB have not been identified in other mycobacterial species, their existence strongly suggests analogous mechanisms elsewhere within the genus.

Additionally, mycobacteria employ deazaflavin-dependent detoxification pathways. The loss of cofactor F420 synthesis has been correlated with increased susceptibility to various antimycobacterial drugs (200). This enhanced sensitivity is primarily due to the essential role of F420-H₂ in enabling reductases to catalyze the detoxification of these antimicrobials (201). Specifically, several F420-dependent reductases from M. smeg are capable of reducing and inactivating toxic compounds (200, 201). Further illustrating this mechanism is the deazaflavin-dependent quinone reductase Ddn, known for activating the prodrug pretomanid (169). Interestingly, Ddn and its homologs such as Rv1261 and Rv1558 have been proposed to also participate in antimicrobial detoxification processes (149). The apparent functional redundancy of Ddn in species like M.tb and M. avium (202), which encode multiple homologs, underscores the robustness of these detoxification mechanisms.

Genome-wide bioinformatic analyses have identified more than 30 distinct flavin/deazaflavin-dependent oxidoreductase (FDOR) homologs within individual mycobacterial species (202). Although directly testing the relationship between flavin-dependent pathways and drug resistance is challenging due to their essential biological roles, pharmacologically targeting flavin biosynthesis may nonetheless enhance mycobacterial sensitivity to existing antimicrobial treatments.

3.1.6 Dormancy/persistence

The success of M.tb and other mycobacteria as pathogens lies in its remarkable ability to persist under intense immunological and antimicrobial pressure. To achieve this persistent state, the bacterium undergoes a profound reorganization of its metabolism, shifting its focus from replication to survival. This metabolic shift is accompanied by a change in drug susceptibility, rendering the bacillus tolerant to multiple antimycobacterial agents (203). One of the major stressors encountered during infection is the reduction in oxygen tension within granulomas (204–207), organized immune structures formed to contain the infection. In response to this hypoxic environment, mycobacteria initiates a transcriptional adaptation orchestrated by the DosRST two-component regulatory system (208). DosS and DosT act as histidine sensor kinases, while DosR serves as the response regulator (209). These kinases sense environmental cues such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S) (209). Upon sensing these gases, DosS and DosT become activated and phosphorylate DosR, which then triggers the upregulation of genes within the Dos regulon. This regulon, comprising approximately 14 to 50 genes depending on the mycobacterial species, includes nitroreductases, ferredoxins, heat shock proteins, diacylglycerol acyltransferases, universal stress proteins, alternative electron transport components, and elements essential for anaerobic respiration (210). Among the two sensor kinases, DosS plays a particularly critical role in sustaining regulon activation and has been classified as flavin-dependent (211). Its activation is linked to its function as a redox sensor, with FMN proposed to participate in signal transduction. However, the exact mechanism through which flavin mediates DosS activation remains incompletely understood. Studies have shown that disruption of the Dos regulon attenuates M.tb, with deletion of dosS causing a more pronounced loss of virulence compared to deletion of dosR or dosT. This suggests that DosS may have functions beyond the classical regulon, potentially coordinating broader responses to environmental stress. Another key player in the dormancy response is Acg (acr co-regulated gene), also known as Rv2032, which is a potential flavin-sequestering protein (212). Acg is part of the Dos regulon and is strongly upregulated under hypoxic conditions (210). Its specific function remains under investigation, but its regulation and structure implicate it as a significant factor in the bacterium’s survival strategy during dormancy which will be discussed further in this review.

In addition to the flavin- and deazaflavin-dependent components discussed, mycobacteria encodes numerous other flavoproteins including several nitroreductases and monooxygenases (82, 107) that contribute to its metabolic versatility and stress adaptation. Collectively, these observations underscore the critical role of flavins and deazaflavin in maintaining mycobacterial physiology. Disruption of flavin and deazaflavin biosynthesis would likely have pleiotropic effects, impairing multiple essential pathways highlighted above. This vulnerability is particularly relevant in the context of rising resistance to current antitubercular regimens. Furthermore, the likelihood of resistance evolving through mutations in the flavin biosynthetic pathway may be limited, given that such mutations could impose significant fitness costs on the bacterium.

3.2 Inhibitors of flavin biosynthesis in mycobacteria

The flavin biosynthetic pathway presents several druggable targets, as five known enzymes within this pathway (RibA2, RibG, RibH, RibC, and RibF) are essential for bacterial viability. Among these, only RibF, a bifunctional riboflavin kinase/FAD synthase, has a homolog in the human host. Since humans are incapable of synthesizing riboflavin, they rely on dietary intake. This riboflavin is subsequently converted to FMN and FAD by separate enzymes, a riboflavin kinase and FAD synthase respectively, whereas both of these functions are carried out by the RibF enzyme in prokaryotes (213). The conservation of the riboflavin kinase domain of RibF between prokaryotes and eukaryotes in both sequence and structure makes it a less druggable target, however the FAD synthase domain displays significant structural divergence which may serve as a drug target (214).

Efforts to design inhibitors targeting this pathway have largely focused on lumazine synthase (RibH) and riboflavin synthase (RibC), primarily through the development of substrate analogs that mimic their natural ligands (215–223). Following the structural and biochemical characterization of these enzymes in B. subtilis and E. coli respectively, an early study successfully identified an inhibitory molecule, which, although a weak inhibitor, served as potent scaffold for further optimization (216). Subsequent studies were able to identify molecules, derivatives of ribitylaminolumazines (218) and purinetrione (217), that exhibited improved binding to the lumazine and riboflavin synthase of E. coli and B. subtilis. These compounds provided a useful scaffold that guided the design of inhibitors against M.tb, with three alkyl phosphate (Figure 4A) derivatives of purinetrione demonstrating nanomolar inhibition of M.tb RibH (224). The resolution of the crystal structure of RibH of M.tb catalyzed the structure-based design and the virtual screening campaigns of libraries for enzyme inhibitors (225–227). The binding mode of the three alkyl phosphate derivatives to M.tb RibH was then determined in order to optimize the design of better inhibitors (228). Subsequently, two derivatives of ribityllumazinediones (Figure 4B) (215) were shown to inhibit the enzymatic activity and bind the RibH of M.tb with high affinity, however their bactericidal activity was not characterized. Beyond the ribityllumazine and purinetrione scaffold, additional novel inhibitors of lumazine and riboflavin synthase have been developed. Derivatives of a sulfur nucleoside analogue of the RibH substrate 5-A-RU (Figure 4C), inhibited both RibH and RibC of M.tb (220). In a follow-up study by the same group, derivatives of O, S, and C nucleoside analogues of 5-A-RU (Figure 4C) also demonstrated inhibitory activities against RibH and RibC (221). Further, a series of three 3-alkyl phosphate derivatives of pyrazolopyrimidine analogues (Figure 4D) were shown to be potent inhibitors of M.tb RibH (223). Another series of oxalamic acid derivatives of 5-A-RU (Figure 4E) was shown to bind RibH and RibC of M.tb with moderate inhibition (Ki) of these enzymes (222). Using a high throughput screen to identify inhibitors of lumazine synthase in Schizosaccharomyces pombe, an analog of 5-A-RU with a substituted ribityl side chain was shown to inhibit M.tb RibH (229, 230) (Figure 4F).

Figure 4

Figure 4. Inhibitors of flavin biosynthesis. This figure summarizes known small-molecule inhibitors of enzymes in the flavin biosynthetic pathway. (A) Derivatives of Purinetrione, (B) Derivatives of Ribityllumazinedione, (C) O, S and N Nucleoside Derivatives of 5-A-RU, (D) Derivatives of Pyrazolopyrimidine, (E) Oxalamic Acid Derivatives of 5-A-RU, (F) Derivatives of 5-A-RU with substituted ribityl side chain, (G) Derivatives of Thiazolidin-4-one, (H) Derivatives of Trifluoromethylated Pyrazoles. For each molecule, target enzyme(s), target species and method of discovery are indicated.

Although most of these compounds identified as inhibitors of RibH have provided important insights into the binding mode of this enzyme, there has been little success in translation to pharmacological agents, likely due to their inactivation by phosphatases (224) or inability to permeate the mycobacterial cell wall (231). However, recent progress in targeting this pathway has led to the identification of novel inhibitors of RibH in M.tb. A recent study using molecular docking of a ~600,000 compound library identified three novel RibH inhibitors with potent antimycobacterial activity and synergy with first-line anti-TB drugs (Figure 4G) (227). Interestingly, these compounds possessed unique chemical scaffolds distinct from traditional substrate mimics, marking a significant shift in the design strategy for RibH inhibitors and potentially for inhibitors of other enzymes in this pathway.

There has also been some success in identifying molecules targeting RibC solely. Kaiser et al. (232) designed an enzymatic photometric read out high-throughput screen for inhibitors of specific riboflavin pathway enzymes. Applying this screening format against a commercial library consisting of 100,000 compounds, they identified 127 hits, with two of them (Figure 4H) showing significant inhibition of M.tb RibC and antimicrobial activity against replicating and non-replicating M.tb (233). However, on-target activity of the compounds had not been confirmed. Serer et al. also developed a unique high-throughput screening platform to search for RibC inhibitors against Brucella sp (234). They employed a mobility shift assay coupled with a microfluidic system, where inhibition was observed as a reduction in the riboflavin fluorescent signal. Screening a 44,000-compound library led to the identification of 10 inhibitors of which three demonstrated moderate growth inhibition even in the presence of riboflavin (234). However, activity of these molecules against M.tb RibC is yet to be determined.

An alternative strategy to inhibit flavin biosynthesis involves targeting the regulation of flavin biosynthesis. Roseoflavin (RoF), a natural riboflavin analog synthesized by Streptomyces exhibits antimycobacterial activity (235). RoF can bind to the FMN riboswitch, leading to the downregulation of RBP genes and consequently reducing riboflavin synthesis (236). Another report documented five riboflavin derivatives, modified at the ribityl moiety that displayed moderate antimycobacterial activity (237). Through in silico docking, and by demonstrating binding affinity to the FMN riboswitch aptamer of Lactobacillus plantarum, FMN riboswitch binding was proposed as one of their mechanisms (237). However, as the presence of an FMN riboswitch in mycobacteria has not been confirmed, the alternative mechanism of RoF and these riboflavin derivatives may explain their antimycobacterial properties. In the case of RoF, it mimics riboflavin and gets converted to inactive cofactors Roseoflavin-5`-monophosphate (RoFMN) and Roseoflavin adenine dinucleotide (RoFAD) which get incorporated into flavoenzymes, either inhibiting or reducing their activity (238). A similar mechanism was also purported for the riboflavin derivatives (237), however, the clinical use of these molecules is impeded by their potential to also disrupt the host flavoproteome. Other inhibitors of riboflavin biosynthesis have also been reported. Ribocil (239), a synthetic small molecule, and 5FDQD (240), a flavin analog, were both shown to be bactericidal to E. coli and Clostridium difficile respectively via repression of RBP genes by binding to the FMN riboswitch. Similar to RoF, the use of these molecules in mycobacteria is impeded by the lack of an FMN riboswitch. However, an approach of disrupting the regulation of flavin biosynthesis in mycobacteria may be employed for drug targeting.

From the studies highlighted above, it is clear that RibH and RibC are the most widely targeted enzymes in the flavin pathway. This preferential targeting likely stems from the better stability and malleability of their substrates and a better understood mechanism of action than the RibA2 and RibG enzymes (231). Although, several inhibitors for RibH and RibC have been identified, most of these compounds were identified through cell-free assays using recombinant enzymes, hence their efficacy as antimycobacterial agents remains uncertain. In vitro and in vivo validation is necessary to assess their translational potential; however, such studies have yet to be reported. Also, studies demonstrating the on-target inhibitory effect on the flavin biosynthetic pathway of these molecules will be essential to demonstrating their mechanism of action. With the advent of tools to better understand the structure and function of these enzymes, the discovery of inhibitors of this pathway should be more approachable. Also, allosteric inhibition of these enzymes may serve as an alternative to substrate mimicry which may facilitate targeting other components of this pathway beyond RibH and RibC.

Four major considerations must be addressed collectively when targeting the flavin biosynthetic pathway pharmacologically. First, the relative vulnerability of mycobacteria to inhibition at different steps of the pathway should be evaluated to identify the most effective enzymatic target. For instance, the presence of two functional lumazine synthase homologs in M.smeg may complicate pharmacological targeting of this enzyme. It is therefore crucial to assess whether similar functional redundancy exists in other pathogenic mycobacterial species. Second, the ideal target should be the component of the pathway most resistant to mutational escape, thereby minimizing the likelihood of developing antimicrobial resistance. Third, given the pathway’s involvement in the biosynthesis of MR1 ligands, the immunological impact of inhibiting different enzymes on MR1-restricted T cell responses must be considered when selecting a therapeutic target. Finally, the impact of targeting the shared pathway (RibA2, RibG) on the administration of deazaflavin dependent prodrugs must be considered. It is well established that disruption of deazaflavin biosynthesis confers resistance to pretomanid and delamanid (93). Therefore, co-administering pretomanid and delamanid with inhibitors of RibA2 or RibG would be impractical. Collectively, the unique mechanism of action associated with flavin pathway inhibitors offers a promising avenue to circumvent existing drug resistance mechanisms and contribute to sustained therapeutic efficacy.

4 Flavin homeostasis and sequestration in mycobacteria

In addition to the substantial energy required to synthesize riboflavin and subsequently FMN and FAD, bacteria must also manage the impact these metabolites have on redox homeostasis. Exposure of reduced flavins to oxygen results in the generation of ROS and flavin radicals, both of which can damage cellular components (241). Therefore, bacteria must tightly regulate flavin biosynthesis and flavin availability to effectively mitigate the potential harm posed by accumulated flavins. Various bacterial species have evolved distinct strategies to address these challenges, including negative feedback regulation mechanisms mediated by riboswitches (101) or the previously mentioned RHOCS (106). Additionally, a highly conserved strategy observed in Actinobacteria species, and shared with archaea (242), involves the sequestration of flavins to prevent oxidative stress (104, 105).

To sequester flavins, mycobacteria utilize specialized flavin-sequestering proteins, three of which have been characterized to date. The first is dodecin, a highly conserved protein across mycobacterial species (105). Structurally, dodecin is a homododecameric protein that preferentially binds FMN (243). Unlike typical flavoproteins, which bind flavins as cofactors for enzymatic reactions, dodecin primarily functions in the sequestration and storage of flavins (242). By doing so, it effectively regulates the availability of free flavins within the bacterial cell. The second characterized protein is the flavin-sequestering protein (Fsq), belonging to the FDOR-B protein family, which is also highly conserved among mycobacteria (244). In contrast to dodecin, Fsq preferentially binds FAD. The expression of the fsq gene is regulated by the DosRS two-component system, distinguishing it from dodecin (244). Another DosRS-regulated protein potentially involved in flavin sequestration is Acg. Encoded adjacent to the gene for Acr (alpha-crystallin protein), Acg is among the most abundantly expressed proteins during hypoxia-induced dormancy (245). Although classified as a putative nitroreductase based on sequence homology, Acg lacks demonstrable enzymatic activity, leading to the hypothesis that its primary role may be flavin storage, particularly binding FMN (246).

Genetic studies have indicated that dodecin, Fsq, and Acg are non-essential in mycobacteria (244, 247, 248), however investigations into their functions under stress conditions have demonstrated significant roles for these proteins in mitigating stressors during infection. Dodecin abundance increases in response to decreasing oxygen levels in hypoxia-induced dormancy models of M.tb and BCG, subsequently returning to baseline levels upon re-exposure to oxygen (249). Additionally, the gene encoding dodecin, rv1498a, is upregulated under acidic conditions and nutrient starvation (250). The biochemical characterization of dodecin also showed that the protein had higher affinity for FMN in acidic environment (105). For Fsq, deletion mutants exhibit impaired growth under hypoxic conditions and delayed reentry into active growth phases (244). Similarly, deletion of Acg leads to reduced fitness in both resting and activated macrophages, highlighting its critical role during the establishment of infection (247). Our group has also reported an increase in the abundance of dodecin, Fsq and Acg in response to elevated riboflavin further buttressing their role in flavin homeostasis (251). Beyond these characterized proteins, sequence homology analyses reveal that mycobacteria encode several other related proteins that may also function in flavin sequestration (252). Considering the likely redundancy among these proteins, future studies aimed at distinguishing their individual contributions will provide deeper insights into mycobacterial physiology and fitness.

The role of flavin sequestering in mycobacteria currently points toward the homeostatic control of flavin and potential generation of radicals. However, it will be important to consider other implications for flavin sequestering. For example, could mycobacteria store flavins for “a rainy day” to be used during scarcity of resources? Since during infection, one of the main stressors encountered by mycobacteria is reduced pH, dodecin may play a role in preventing further damage from redox stressors created by excess flavins. Stored flavins may also serve as a source of essential cofactors upon reentry into active growth. Congruently, fsq mutants were shown to have an impaired ability to recover from hypoxia induced dormancy (244). Answering such questions will be necessary to optimize targeting this pathway to ensure that upon inhibition of flavin biosynthesis, the bacilli is unable to use stored flavins for baseline functions until the inhibitory agent is withdrawn. Hence, the role of flavin sequestering in mycobacterial physiology must be further elucidated.

5 Role of flavin and deazaflavin biosynthesis in MR1 antigenicity and vaccine development

T-cell immunity plays a critical role in controlling mycobacterial infections (253, 254). Beyond the classical CD4- and CD8-restricted T-cell populations, non-classically restricted T-cells, including CD1-restricted (255), γδ (256), and MR1-restricted (257, 258) T-cells, also contribute to antimycobacterial immunity (259). For decades, the antigens recognized by these unconventional T-cells remained elusive, however recent discoveries have revealed that these cells primarily respond to metabolites (57, 255). CD-1 restricted T-cells, particularly Natural killer T (NKT) cells recognize lipids and glycolipids, while the specific ligands for γδ T-cells remain unclear. MR1T cells, including MAIT cells, recognize intermediates and secondary products of the RBP (57, 65, 260, 261). These findings have significantly shifted the paradigm of T-cell antigen recognition. In this section, we cover the immunology, ligandome and vaccine potential of MR1T cells for mycobacterial infection.

5.1 MR1 and its immunological significance during mycobacterial infection

MR1 is the most conserved antigen presenting molecule in mammals (262, 263). For instance, the critical antigen binding domains of MR1, the α1 and α2 domains are 90% conserved between mice and humans (263, 264). This high degree of conservation suggests that MR1 plays a fundamental and evolutionarily important function in the immune system that has therefore been maintained by evolutionary pressure (262). MR1T cells were first described in 1993, as a common type of CD4^-CD8^-cell expressing an invariant TCR α-chain (TRAV1-2/TRAJ33) (265). These TRAV1–2 expressing cells were later termed MAIT cells given their invariant α-chain, enrichment in mucosal surfaces and later demonstrated to be restricted by MR1 (266). We now recognize that MAIT cells are only a subset of the broader class of MR1T cells. In adults, MAIT cells are the most common MR1T cell and are defined by their expression of an invariant TCR α-chain (TRAV1-2/TRAJ33/20/12 in humans), paired with a limited array of Vβ segments (267, 268), and often express high levels of CD161 (269, 270) and CD26 (271). MR1T cells have been shown to play an important role in microbial defense, providing protection against many different riboflavin producing pathogens, including Klebsiella pneumoniae (272), E. coli (260), Francisella tularensis (273), Streptococcus pneumoniae (274), and mycobacterial pathogens (64, 65, 275).

MR1T cells have many features that make them well suited for defense against a wide variety of pathogens. They are enriched in mucosal surfaces, including the lung (276) and gastrointestinal tract (277), the first contact point for most infections. They do not require priming and are therefore able to respond much more rapidly than conventional T cells. They respond with production of critical inflammatory cytokines including IFNγ and TNF, but also with a robust cytotoxic response, more so than conventional T cells and this may be particularly important for intracellular pathogens such as M.tb (276). Insights from key studies support the immunological importance of MR1 in M.tb defense, including both animal models and human studies. In murine models, MR1 knockout mice exhibit worse control of BCG infection, showing the role of MR1 in mycobacterial defense (275). In non-human primates (NHPs), blocking CD8a to deplete all CD8⁺ cells, including non-conventional T cells like MR1T cells, had a profound impact on bacterial control and dissemination, whereas blocking CD8b to only deplete conventional CD8-positive cells had only a modest effect on lymph node bacterial control (278). Using a similar model, this same group demonstrated that the protection given to NHPs from IV BCG was lost with CD8a depletion, but not CD8b depletion (279). These studies highlight the important role non-conventional CD8-positive T cells, such as MR1T cells, play in control of M.tb, but also in vaccine-mediated protection from M.tb. Human studies further reinforce MR1’s role in TB defense, with MR1T cells being higher in a Ugandan cohort of TB resisters (280). Additionally, MR1 polymorphisms have been associated with severe and disseminated TB, underscoring the clinical relevance of MR1 in TB pathogenesis (257).

5.2 Heterogeneity of MR1 TCR and ligands

Since the initial discovery that intermediates of the RBP serve as ligands for MR1T cells, many other ligands have been discovered, with some functioning as agonists (261, 264) and others as antagonists (87, 258). Among the most potent agonists are 5-OP-RU and 5-OE-RU (Figure 5) which bound to majority of the known MR1T cells TCRs (125). This potency was leveraged to develop a MR1-tetramer loaded with 5-OP-RU that allowed researchers to study MR1T cells that do not express canonical markers attributed to MR1T cells (267). The use of MR1-tetramers led to the discovery of TRAV1-2 (–) MR1T cells including MR1T cells that recognized the riboflavin auxotroph, Streptococcus pyogenes, in an MR1-dependent manner. These findings started to disprove the hypothesis that the TCR of these T cells were highly invariant. These findings have also spurred investigations to determine the full repertoire of TCRs utilized by MR1T-cells as well as how this impacts the recognition of ligands presented by MR1.

Figure 5

Figure 5. MR1 ligands observed in mycobacteria. MR1 antigens from the flavin and deazaflavin biosynthetic pathway in Mycobacteria. Box 1: 5-A-RU is central to the production of MR1 ligands. Box 2: 5-A-RU reacts non-enzymatically with glyoxal and methylglyoxal, byproducts of glycolysis, to form OE-RU and OP-RU respectively. These products condense to form more stable products: RL and RL-7-Me respectively. Box 3: 5-A-RU serves as a precursor for the synthesis of several MR1 ligands, including DMRL, PL I, PL III, and PL IV. While the PLs have only been observed in M. smeg, their immediate biosynthetic precursor remains unidentified. Box 4: Riboflavin and F0, intermediates of flavin and deazaflavin biosynthesis have been shown as MR1 ligands with antagonistic properties. (Image created with Biorender.com). 5-OP-RU, 5-(-2-oxopropylideneamino)-6-D-ribitylaminouracil; 5-OE-RU, 5-(-2-oxoethylideneamino)-6-D-ribitylaminouracil; RL-7-Me, 7-methyl-8-D-ribityllumazine; RL, ribityllumazine; 5-A-RU, 5-amino-6-D-ribitylaminouracil; DMRL, 6,7-dimethyl-8-ribityllumazine; PL, photolumazine.

Following the development and expansion of MR1T cells over time has contributed to the observed heterogeneity in their TCR repertoire. Although the majority of MR1T cells in adults are identified as belonging to the subclass of MAIT cells and express the TRAV1–2 chain, this has been shown to differ from what is observed at birth. Using the MR1/5-OP-RU tetramer, the majority of the tetramer(+) cells at birth were identified to be TRAV1-2 (–) (65). Recent work performing TCR sequencing of MR1/5-OP-RU tetramer(+) MR1T cells at birth has further shown that this TCR diversity extends beyond just alternate TRAV usage, with tremendous diversity in TCR usage similar to what is observed in conventional T cells (281). These more diverse cord blood derived MR1T cells were less able to recognize riboflavin producing microbes, suggesting that they may recognize a more diverse array of ligands. Further demonstrating this heterogeneity of MR1T TCRs and the antigens they recognize, work done by Gold et al. showed that different clones of MR1T cells were capable of recognizing riboflavin-producing organisms (S. typhimirium, C. albicans and M.smeg) in an MR1 dependent manner. However, only some of these clones could recognize the ligand 6,7-dimethyl ribityl lumazine (RL-6,7-diMe) (282). This finding indicates that, even in the context of the ligands derived from the RBP, there is a diversity of ligands.

Similar to the discovery of the diversity of TCR of MR1T cells, understanding of the molecules thought to be presented by MR1 has changed drastically over the years with the discovery of different classes of molecules including folic acid derivatives (57, 125), pyridoxal derivatives (261), nucleobase derivatives (283–285). The diversity of ligands presented by MR1 was further explored by Harriff et al. who used mass spectrometry to examine the E.coli and M.smeg ligand repertoire presented by MR1 (258). Some ligands were only observed in M.smeg and these activated some, but not all, of the MR1T cells clones used in the study. This finding suggests that MR1T cells are capable of discriminating between pathogen-specific ligand repertoires through TCR dependent recognition. Collectively, these studies support the idea that MR1T cells can mount tailored responses to distinct microbial exposures, rather than acting as a uniform invariant population responding to a single conserved antigen. Ultimately, these findings legitimizes the need to identify MR1 ligands, in this case, ligands specific to the mycobacteria genus and species.

5.3 The MR1 ligandome of mycobacteria

Since the discovery of 6-formylpterin (5-FP) and 5-OP-RU, the first MR1 antagonist and agonist respectively (57, 125), the list of MR1 ligands has expanded to include both naturally occurring and synthetic molecules. With the recent uncovering of the heterogeneity of TCR utilized by MR1T cells and the binding pocket of MR1 shown to be potentially receptive to other molecules beyond those currently identified, the MR1 ligandome is likely to keep expanding. Here, we will discuss currently identified MR1 ligands in mycobacteria, the current state of research probing the mycobacterial MR1 ligandome and their potential role as immunomodulators.

MR1 ligands are currently classified as antagonist and agonists based on their ability to induce MR1 expression and interact with the TCR of MR1T cells. For both agonists and antagonists, these molecules can be loaded on MR1 in the endoplasmic reticulum (ER) of antigen presenting cells (286, 287), where unloaded MR1 molecules reside, and induce the egress of MR1 to the cell surface where it presents the loaded molecule to the cognate TCR (288). At the point of interaction between the loaded MR1 and the TCR comes the distinction between agonists and antagonists. Agonists induce a response via the TCR activation of MR1T cells leading to cytotoxic activity and the release of proinflammatory cytokines (289). Conversely, antagonists may interact with the TCR but do not induce an immune response (290). This antagonistic property has been shown to prevent TCR dependent activation of MR1T cells via agonists as antagonist loaded MR1 are unable to present agonistic ligands. This competitive inhibition of MR1 agonists presentation by antagonists has been shown experimentally and may play a role in immunomodulation (290). Conversely, the antagonist induced egress of MR1 to the cell surface has also been shown to facilitate the loading of agonist from the extracellular milieu via a yet-to-be-defined exchange mechanism (291). However, it is still unclear how much this exchange mechanism contributes to MR1 antigen presentation during infection. Recently, another mechanism of MR1 antagonism was discovered where antagonists retain MR1 in the ER and prevent its egress to the cell membrane (292). As opposed to antagonists that induce surface expression, antagonists that prevent egress prevent antigen loading both in the ER and the exchange at the plasma membrane. Currently, only synthetic molecules have been shown to utilize the egress-inhibition mechanism. However, the evidence of such mechanism indicates a likelihood of a mycobacteria derived ligand possessing such property.

The FBP and DBP in mycobacteria have been shown to produce both agonistic and antagonistic ligands of MR1 (Figure 5). DMRL, is a well-established MR1 agonist, albeit to a lesser extent in comparison to 5-OP-RU (290, 293). F0 and riboflavin have also been shown to be loaded on MR1, although activation studies showed that they had antagonistic properties (258). Beyond these intermediates, photolumazines have also been observed in the environmental M.smeg, as previously discussed. Harriff et al. identified Photolumazine I and III using recombinant MR1 in insect cells (258) (Figure 5). Krawic and Ladd et al. also identified four isomers of Photolumazine IV in M.smeg using a similar system (294) (Figure 5). Although none of these ligands have been identified in pathogenic mycobacteria, their discovery provides some context on the expanding family of MR1 ligands in mycobacteria. When these ligands were discovered, they were initially thought to be derivatives of DMRL. However, two recent studies indicate that they are likely derived from 5-A-RU instead. As earlier stated, 5-A-RU was shown to form lumazines, including Photolumazine III, through condensation reactions with transamination products in E. coli (126). Also, we recently showed the centrality of 5-A-RU to produce MR1 ligands in mycobacteria. Mutants of M.smeg and M.tb that lacked RibA2 or RibG were unable to activate MR1T cell clones (295). Interestingly, the loss of DMRL production had little to no impact on MR1T cell activation. Since 5-A-RU itself is not loaded onto the MR1 ligand groove (57), it is hypothesized that 5-A-RU primarily serves as a primer for the synthesis of MR1 ligands. This hypothesis is further corroborated by the ubiquitous nature of 5-A-RU in all riboflavin competent organisms (231). However, 5-A-RU serving as an antigen does not account for the unique MR1 ligandome of different organisms. The findings from these studies, as well as those in the previous section, highlight the need to discover these mycobacterial ligands and understand how they impact MR1 immunology during infection and how the metabolic status of mycobacteria impacts their abundance.

The pathogenic success of mycobacterial species, particularly M.tb, partially relies on their capability to modulate the host immune response during infection. The production of MR1 agonists (such as DMRL) and antagonists (such as F0) by mycobacteria highlights their potential role as immunomodulatory agents. Furthermore, during infection of a host, mycobacteria can assume several phenotypically distinct states due to the plasticity of its metabolic landscape (296, 297). This plasticity enables mycobacteria to establish itself as a highly heterogenous population dependent on stressors encountered in host (298–302). These populations differ in cell wall composition, replication dynamics and kinetics, and the status of CCM and accessory pathways. This metabolic plasticity exhibited by mycobacteria enables dynamic alterations in metabolic antigenicity, thus influencing host-pathogen interactions. It is possible that mycobacteria utilize a similar mechanism to modulate surveillance by MR1T cells as its reliance on flavins may change in some of these states. Proteomic analysis of M.tb during hypoxia showed a transient increase in the abundance of all the proteins in the riboflavin and deazaflavin pathway except for fbiB (249). In the same study, they also observed an increased abundance of FMN and decreased abundance of 5-A-RU and DMRL as oxygen levels depleted (249). It is unclear how these changes may impact MR1 antigenicity as the flux of these intermediates toward downstream products cannot be predicted from this data. Hence, further investigation is necessary to determine how these changes in the proteome and metabolome during hypoxia and other stress-induced dormancy impact the MR1 ligandome of mycobacteria.

It is also clear that the immunological pressure faced by mycobacteria influences its genetic evolution (303, 304). Given the importance of MR1 during mycobacterial infection, it will be important to determine evolutionary changes that might have impacted flavin and deazaflavin biosynthesis in mycobacteria. It was observed that a clinical strain of Salmonella enterica had evolved to overexpress ribB, the gene that encodes the equivalent of the DHBP synthase activity of ribA2 in mycobacteria, evaded recognition by MAIT cells (305). Although, it was uncertain how the overexpression of this gene impacted MR1 ligand production, the investigators observed higher levels of extracellular riboflavin and FMN in the ribB overexpressor. It is possible that the overproduction of DHBP may drive the pathway toward the synthesis of DMRL and riboflavin and prevent the buildup of 5-A-RU, the required intermediate for MR1 antigens. Similarly, a pathogenic strain of F. tularensis was shown to harbor mutations in the ribA2 gene which negatively impacted MAIT cell activation, a phenotype shown to enhance virulence (306). Another study investigating the impact of overexpressing the rib pathway genes in mycobacteria showed increased MAIT activation and decreased virulence in the mouse model when ribA2 was overexpressed (307). This finding was shown to be MAIT cell dependent as infection of CAST/EiJ mouse model, which has an increased frequency of MAIT cells, led to better protection. Earlier studies in the 1930s attempted, without success, to link riboflavin production with virulence (68). Given recent findings, their original hypothesis may indeed have merit and warrants renewed investigation.

Current research on MR1 ligands in mycobacterial species has predominantly focused on M.smeg and M.tb. However, the emerging evidence of a broader MR1 ligandome than previously recognized, with species-specific variations, highlights the need to expand ligand characterization efforts to NTMs and M. leprae, which exhibit distinct metabolic profiles compared to M.tb (8). Growth rate differences between rapid- and slow-growing mycobacteria likely impact the dependence on and the flux of the intermediates through the flavin/deazaflavin biosynthesis. This metabolic divergence suggests pathogen-specific ligand signatures which may influence the role of MR1T cells during infection. With recent advancements in mass spectrometry and bioinformatic tools, the identification of novel natural compounds has become significantly more feasible. It is now an opportune moment to leverage these powerful technologies to systematically identify and characterize MR1 ligands. Discovering both flavin-related and non-flavin-related ligands represents an essential step toward elucidating their roles in MR1-mediated immune responses during mycobacterial infections. Furthermore, pinpointing these ligands will facilitate optimal targeting of MR1-restricted immune cell populations, particularly those residing at the site of infection, enhancing both immunotherapeutic and vaccine development strategies.

5.4 Potential of MR1 ligand in vaccines/therapeutics design

MR1T cells have many features that make them attractive vaccine targets. In addition to being enriched in mucosal surfaces (276), the main sites of most initial infections, they are activated more rapidly than conventional T cells, and they have robust cytotoxic capabilities (Figure 6) (308). Furthermore, MR1T cells are also active against a broad array of pathogens for which no effective vaccine currently exists. Importantly, unlike the highly polymorphic Major Histocompatibility Complex (MHC), the antigen-presenting molecules that restrict these unconventional T-cells are non-polymorphic (262, 266, 308). This has major implications for vaccine design. Genetic variations in Human Leukocyte Antigen (HLA) genes influence immune responses to vaccination, posing a challenge to developing universal vaccine strategies. In contrast, MR1’s non-polymorphic nature, and the consequent donor-unrestricted characteristics of MR1T cells, suggest that genetic variability is less likely to affect vaccine efficacy.

Figure 6

Figure 6. Activation of MR1 restricted T-cells. MR1 restricted T-cells expressing canonical markers of MAIT cells. Box 1: Activation of MR1T cells via a T-cell receptor (TCR) independent mechanism leading to production of pro-inflammatory cytokines. MR1-independent activation is by cytokine stimulation, particularly by inflammatory cytokines such as IL-12 and IL-18. Box 2: Activation of MR1T-cells via a TCR dependent mechanism leading to production of pro-inflammatory cytokines and killing of infected cell. T cell receptor (TCR) activation through MR1, the major histocompatibility complex (MHC)-related protein, is mediated by the recognition of MR1-presented metabolites, predominantly by MAIT cells. MR1 is activated by microbially derived riboflavin intermediates together with co-stimulatory signaling. (Image created with Biorender.com). APC, Antigen Presenting Cell.

In mouse models, 5-OP-RU was explored as a vaccine candidate to activate MR1T cells for protection against M.tb and while there was robust expansion of MR1T cells in the lung, this was not associated with protection (309). This was also attempted in NHP models, and similarly, 5-OP-RU did not provide protection against M.tb, and in fact led MR1T cells to upregulate PD-1 and lose the ability to produce important cytokines such as IFN-γ (310). Although these initial attempts have been unsuccessful, we are only just beginning to understand the complex biology and MR1T cell activation, and utilizing a very broad activating antigen such as 5-OP-RU may not be an appropriate strategy. Work from Riffelmacher et al. (274) has shown that vaccination with the live attenuated Salmonella vaccine strain, BRD509, in mouse models led to an expansion of lung-resident antigen adapted MR1T cells with enhanced effector programs. This expansion was associated with a protection against subsequent Streptococcus pneumoniae infection, providing proof of concept for an MR1T-based vaccine strategy capable of conferring cross-species protection in mice (274). Additionally, several studies have shown the capacity of MR1T cells to assume an innate memory-like phenotype (273, 276, 277, 311–316). In particular, recent work by Kain et al. showed that following BCG vaccination, there was an expansion of MR1T meta-clonotypes with increased expression of pro-inflammatory and cytotoxic genes, indicative of a recall-like response to prior vaccination (316). Systematically boosted MR1T cell were shown to induce protection against Francisella tularensis a month after vaccination with the MR1 agonist, 5-OP-RU (273). Using a similar vaccination strategy, the expansion of lung resident MR1T cells a month prior to infection with Legionella longbeachae led to a significant reduction in bacterial burden (315). A recent study showed that Listeria monocytogenes, a riboflavin auxotroph, engineered to produce riboflavin conferred protection against F. tularensis when used as a vaccine (312). These findings provide evidence of sustainable MR1T cell expansion enabling the development of vaccination strategies targeting MR1T cells. Since most of the studies assessing the vaccine-targeting potential of MR1T cells have evaluated immune response within only a few weeks to a month, further research is required to determine the long-term persistence of the innate, memory-like phenotype of MR1T cells. Understanding the duration and stability of this response will be critical for defining the most effective vaccination strategy that can optimally engage and sustain MR1T cell-mediated immunity.

With the growing recognition of the critical role of MR1T cells during M.tb infection, several studies have examined the impact of BCG vaccination on MR1T cell-mediated (316–319). BCG vaccination was shown to modulate the MR1T cell landscape at infancy suggesting its capacity to induce an MR1T cell-mediated response (316). Similarly, BCG revaccination in adults was shown to expand the MR1T cell population, a finding that was recapitulated in non-human primates (317, 319). However, although BCG clearly induces an MR1T cell response, the longevity and the extent to which this response contributes to protection against M.tb remains unclear. Furthermore, confirming the similarity between the MR1 ligandome and TCR repertoires elicited by BCG and those triggered by M.tb infection is essential to establish effective cross-induction. Finally, identifying the optimal route of BCG administration to maximize the activation of both conventional and unconventional T cells, including MR1T cells, remains an important consideration for vaccine optimization (320).

Although 5-OP-RU broadly activated the majority of MR1T cells, it has been shown that MR1T cells have antigen selectivity (258, 282), and thus the choice of antigen that leads to expansion could play an important role in subsequent protection from infection in a manner akin to conventional T cells. Furthermore, MR1T cells are also cytokine responsive, and activation of MR1T cells in the setting of different cytokine exposure can influence the functional ability of MR1T cells. For example, Wang et al. have recently shown that MR1T cell clones can be induced to switch from IL-17-producing clones to IFNγ-producing clones (311). Thus, it is entirely possible that it is not just the antigen that activates MR1T cells that is important in inducing protection from these cells, but also the cytokine environment that shapes their eventual function and ability to protect against subsequent infection.

Given these facts, identifying MR1 ligands unique to mycobacteria will proffer several advantages in the design of vaccines targeting MR1T cells, Firstly, it will be able to optimize the delivery of the antigens to the right population of immune cells and anatomical region. Secondly, using tetramers loaded with these ligands, it will be feasible to track how different vaccines strategies impact the expansion and function of cognate MR1T cells. Most importantly, the best strategy to ensure the development of memory MR1T cells can be determined. Furthermore, metabolite recognition offers advantages over peptide antigen recognition. Peptide-based immune responses are influenced by post-translational modifications, protein-protein interaction and protein secondary structures, whereas metabolite recognition is comparatively simpler. Additionally, synthesizing and manipulating small molecules is more feasible than working with peptides, making them attractive targets for vaccine development (321, 322).

6 Challenges and future directions

Flavin and deazaflavin biosynthesis pathways in mycobacteria occupy a unique position at the intersection of antimicrobial discovery and vaccine development, as summarized in Figure 7. While deazaflavins contribute significantly to the activation of prodrugs with potent antimycobacterial properties, the rise of resistance mechanisms underscores the urgency to explore novel intervention strategies. Because flavins and deazaflavins are important cofactors for over 160 mycobacterial proteins, most of which remain poorly characterized (107), it is imperative to prioritize functional characterization studies of these flavoproteins and associated enzymes. Although the structural elucidation of many enzymes within these pathways has advanced substantially, critical gaps remain in our understanding of their roles during infection.

Figure 7

Figure 7. Summary of review. (Image created with Biorender.com).

In this review, we demarcate FBP and DBP into three components that should be taken into consideration for investigating therapies targeting these pathways. Targeting the shared biosynthetic pathway by disrupting 5-A-RU production, crucial for flavin, deazaflavin, and MR1 antigen synthesis, could profoundly impact MR1-mediated immune responses. It remains essential to assess whether impairing MR1 antigen availability significantly compromises host immunity against mycobacterial infections. Alternatively, inhibiting downstream enzymes, such as those involved in the production of DMRL offers a balanced approach, allowing simultaneous administration of deazaflavin-dependent antimicrobials while preserving MR1 antigen presentation. Additionally, targeting F0 biosynthesis to prevent MR1 antagonism by mycobacteria could further strengthen host immune responses by restricting bacterial immune evasion strategies. Hence, it will be necessary to determine the role of MR1 antagonists in in vivo models and determine if blocking F0 or 5-A-RU biosynthesis outweighs the benefit of being able to administer deazaflavin-dependent pro-drugs or the continuous production of MR1 antigens.

Progress in identifying novel MR1 ligands and understanding how structural variations of these molecules influence MR1-restricted T-cell responses is critical. Drawing parallels from other unconventional T-cell systems, such as invariant NKT cells, investigating whether modified MR1 ligands can similarly drive polarized immune responses (pro-inflammatory versus anti-inflammatory) could have profound implications for vaccine design and therapeutic modulation. Moreover, delineating the rules governing cross-reactivity of MR1T-cell receptors, distinguishing responses triggered by exogenous versus endogenous MR1 ligands, and clarifying the physiological significance of extracellular riboflavin represent fundamental questions needing further exploration.

Animal studies employing flavin and deazaflavin biosynthetic mutants, particularly in models that more accurately reflect human MR1T-cell populations, will be instrumental in advancing our understanding of these pathways in granuloma formation and host-pathogen interactions. Given that mycobacteria are unable to scavenge riboflavin or deazaflavin from the host (109), such models will also clarify the impact of targeting these biosynthetic routes on bacterial viability and disease pathology during infection. Additionally, utilizing mutants of flavin-sequestering proteins will provide insights into their functional roles in vivo. Moreover, the limited efficacy of 5-OP-RU as a vaccine adjuvant underscores the urgency of identifying physiologically relevant MR1 ligands. These experimental models could be leveraged to explore the contribution of MR1 ligands to the immunological landscape of mycobacterial infection. Ultimately, elucidating how mycobacteria infection modulates host flavoproteins, and how various environmental stressors influence these pathways, will be critical for informing the next generation of antimycobacterial therapeutics and vaccine strategies. Collectively, addressing these research questions holds the potential to unlock novel avenues for targeting flavin and deazaflavin biosynthesis, thereby driving innovation in the development of antimicrobial therapies and vaccines against mycobacterial diseases.

7 Conclusion

In this review, we have explored the biosynthetic pathways of flavin and deazaflavin in mycobacteria, highlighting their critical roles in the physiology and immunological interactions of this bacilli. We examined how the products of these pathways contribute to metabolic adaptation, stress resistance, host-pathogen interaction and MR1 antigenicity. Additionally, we discussed the emerging concept of flavin sequestration and its potential role as an integral component of mycobacterial survival. Finally, we outlined key considerations for future research aimed at elucidating these pathways, emphasizing their promise as targets for novel drug development and vaccine strategies. Together, these insights underscore the multifaceted importance of flavin and deazaflavin metabolism in mycobacterial pathogenesis and control.

Author contributions

NO: Writing – review & editing, Investigation, Conceptualization, Software, Formal analysis, Writing – original draft, Data curation, Visualization. MC: Writing – original draft, Visualization, Writing – review & editing, Investigation. DK: Writing – original draft, Writing – review & editing, Investigation. DL: Writing – review & editing, Supervision, Validation. KD: Validation, Writing – review & editing, Conceptualization, Supervision.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Institute of Health UC7AI180308 , R01AI147954 and 3G20AI167348-01S1.

Acknowledgments

The authors acknowledge Megan Lucas, Ph.D. and Luisa Nieto Ramirez, Ph.D. for critical reading of the manuscript.

Conflict of interest

The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1656167/full#supplementary-material

References

1. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. (1959) 43:273–90. doi: 10.1016/S0025-7125(16)34193-1, PMID: 13612432

PubMed Abstract | Crossref Full Text | Google Scholar

2. Rastogi N, Legrand E, and Sola C. The mycobacteria: an introduction to nomenclature and pathogenesis. Rev Sci Tech Int Off Epizoot. (2001) 20:21–54. doi: 10.20506/rst.20.1.1265, PMID: 11288513

PubMed Abstract | Crossref Full Text | Google Scholar

3. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis. (1992) 15:1–12. doi: 10.1093/clinids/15.1.1, PMID: 1617048

PubMed Abstract | Crossref Full Text | Google Scholar

4. Brown-Elliott BA and Philley JV. Rapidly growing mycobacteria. Microbiol Spectr. (2017) 5. doi: 10.1128/microbiolspec.tnmi7-0027–2016

Crossref Full Text | Google Scholar

5. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature. (2001) 409:1007–11. doi: 10.1038/35059006, PMID: 11234002

PubMed Abstract | Crossref Full Text | Google Scholar

6. Global tuberculosis report (2024). Available online at: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024 (Accessed May 26, 2025).

Google Scholar

7. Global leprosy (Hansen disease) update, 2023: Elimination of leprosy disease is possible – Time to act! (2025). Available online at: https://www.who.int/publications/i/item/who-wer9937-501-521 (Accessed May 26, 2025).

Google Scholar

8. Johansen MD, Herrmann JL, and Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. (2020) 18:392–407. doi: 10.1038/s41579-020-0331-1, PMID: 32086501

PubMed Abstract | Crossref Full Text | Google Scholar

9. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. (2020) 11:303/full. doi: 10.3389/fimmu.2020.00303/full, PMID: 32194556

PubMed Abstract | Crossref Full Text | Google Scholar

10. Falkinham JO. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. (2015) 36:35–41. doi: 10.1016/j.ccm.2014.10.003, PMID: 25676517

PubMed Abstract | Crossref Full Text | Google Scholar

11. Adjemian J, Olivier KN, and Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States. Screening practices and environmental risk. Am J Respir Crit Care Med. (2014) 190:581–6. doi: 10.1164/rccm.201405-0884OC, PMID: 25068291

PubMed Abstract | Crossref Full Text | Google Scholar

12. Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol. (2009) 47:4124–8. doi: 10.1128/JCM.01257-09, PMID: 19846643

PubMed Abstract | Crossref Full Text | Google Scholar

13. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, and Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. (2013) 17:e1000–1004. doi: 10.1016/j.ijid.2013.03.018, PMID: 23683809

PubMed Abstract | Crossref Full Text | Google Scholar

14. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, and Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. (2013) 68:256–62. doi: 10.1136/thoraxjnl-2012-201772, PMID: 22781123

PubMed Abstract | Crossref Full Text | Google Scholar

15. Collins FM. AIDS-related mycobacterial disease. Springer Semin Immunopathol. (1988) 10:375–91. doi: 10.1007/BF02053847, PMID: 3065953

PubMed Abstract | Crossref Full Text | Google Scholar

16. Collins FM.Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clin Microbiol Rev. (1989) 2:360–77. doi: 10.1128/cmr.2.4.360, PMID: 2680057

PubMed Abstract | Crossref Full Text | Google Scholar

17. Cassidy PM, Hedberg K, Saulson A, McNelly E, and Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: A changing epidemiology. Clin Infect Dis. (2009) 49:e124–9. doi: 10.1086/648443, PMID: 19911942

PubMed Abstract | Crossref Full Text | Google Scholar

18. Song HW, Tian JH, Song HP, Guo SJ, Lin YH, and Pan JS. Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends. Front Public Health. (2024) 12:1408316/full. doi: 10.3389/fpubh.2024.1408316/full, PMID: 39319291

PubMed Abstract | Crossref Full Text | Google Scholar

19. Lv H, Zhang X, Zhang X, Bai J, You S, Li X, et al. Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019. BMC Infect Dis. (2024) 24:243. doi: 10.1186/s12879-024-09079-5, PMID: 38388352

PubMed Abstract | Crossref Full Text | Google Scholar

20. Aubry A, Sammarco Rosa P, Chauffour A, Fletcher ML, Cambau E, and Avanzi C. Drug resistance in leprosy: An update following 70 years of chemotherapy. Infect Dis Now. (2022) 52:243–51. doi: 10.1016/j.idnow.2022.04.001, PMID: 35483633

PubMed Abstract | Crossref Full Text | Google Scholar

21. Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clin Microbiol Infect. (2018) 24:1305–10. doi: 10.1016/j.cmi.2018.02.022, PMID: 29496597

PubMed Abstract | Crossref Full Text | Google Scholar

22. Nguyen TQ, Heo BE, Jeon S, Ash A, Lee H, Moon C, et al. Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches. Front Microbiol. (2024) 15:1331508. doi: 10.3389/fmicb.2024.1331508, PMID: 38380095

PubMed Abstract | Crossref Full Text | Google Scholar

23. Griffith DE. Mycobacterium abscessus and antibiotic resistance: same as it ever was. Clin Infect Dis. (2019) 69:1687–9. doi: 10.1093/cid/ciz071, PMID: 30689764

PubMed Abstract | Crossref Full Text | Google Scholar

24. Luthra S, Rominski A, and Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in mycobacterium abscessus drug resistance. Front Microbiol. (2018) 9:2179/full. doi: 10.3389/fmicb.2018.02179/full, PMID: 30258428

PubMed Abstract | Crossref Full Text | Google Scholar

25. Nessar R, Cambau E, Reyrat JM, Murray A, and Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. (2012) 67:810–8. doi: 10.1093/jac/dkr578, PMID: 22290346

PubMed Abstract | Crossref Full Text | Google Scholar

26. Aung TT, Yam JKH, Lin S, Salleh SM, Givskov M, Liu S, et al. Biofilms of pathogenic nontuberculous mycobacteria targeted by new therapeutic approaches. Antimicrob Agents Chemother. (2015) 60:24–35. doi: 10.1128/AAC.01509-15, PMID: 26459903

PubMed Abstract | Crossref Full Text | Google Scholar

27. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, and Pace NR. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci. (2009) 106:16393–9. doi: 10.1073/pnas.0908446106, PMID: 19805310

PubMed Abstract | Crossref Full Text | Google Scholar

28. Luca S and Mihaescu T. History of BCG vaccine. Mædica. (2013) 8:53–8.

Google Scholar

29. Hatherill M and Cobelens F. Infant BCG vaccination is beneficial, but not sufficient. Lancet Glob Health. (2022) 10:e1220–1. doi: 10.1016/S2214-109X(22)00325-4, PMID: 35961334

PubMed Abstract | Crossref Full Text | Google Scholar

30. Duthie MS, Gillis TP, and Reed SG. Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin. (2011) 7:1172–83. doi: 10.4161/hv.7.11.16848, PMID: 22048122

PubMed Abstract | Crossref Full Text | Google Scholar

31. Abate G, Hamzabegovic F, Eickhoff CS, and Hoft DF. BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity. Front Immunol. (2019) 10:234/full. doi: 10.3389/fimmu.2019.00234/full, PMID: 30837992

PubMed Abstract | Crossref Full Text | Google Scholar

32. Zimmermann P, Finn A, and Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. J Infect Dis. (2018) 218:679–87. doi: 10.1093/infdis/jiy207, PMID: 29635431

PubMed Abstract | Crossref Full Text | Google Scholar

33. The end TB strategy (2025). Available online at: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/the-end-tb-strategy (Accessed May 26, 2025).

Google Scholar

34. Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021–2030 (2025). Available online at: https://www.who.int/publications/i/item/9789290228509 (Accessed May 26, 2025).

Google Scholar

35. Mudde SE, Upton AM, Lenaerts A, Bax HI, and De Steenwinkel JEM. Delamanid or pretomanid? A Solomonic judgement! J Antimicrob Chemother. (2022) 77:880–902. doi: 10.1093/jac/dkab505, PMID: 35089314

PubMed Abstract | Crossref Full Text | Google Scholar

36. Organization WH. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. Geneva: World Health Organization (2013). Available online at: http://www.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf?ua=1.

Google Scholar

37. Ahmad Khosravi N, Sirous M, Khosravi AD, and Saki M. A narrative review of bedaquiline and delamanid: new arsenals against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis. J Clin Lab Anal. (2024) 38:e25091. doi: 10.1002/jcla.25091, PMID: 39431709

PubMed Abstract | Crossref Full Text | Google Scholar

38. Lei B, Wei CJ, and Tu SC. Action mechanism of antitubercular isoniazid. J Biol Chem. (2000) 275:2520–6. doi: 10.1074/jbc.275.4.2520, PMID: 10644708

PubMed Abstract | Crossref Full Text | Google Scholar

39. Goude R, Amin AG, Chatterjee D, and Parish T.The arabinosyltransferase embC is inhibited by ethambutol in mycobacterium tuberculosis. Antimicrobial Agents Chemotherapy. (2025) 53:4138–46. doi: 10.1128/aac.00162-09, PMID: 19596878

PubMed Abstract | Crossref Full Text | Google Scholar

40. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. (2001) 104:901–12. doi: 10.1016/s0092-8674(01)00286-0, PMID: 11290327

PubMed Abstract | Crossref Full Text | Google Scholar

41. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. (2010) 17:1152–3. doi: 10.1038/nsmb.1892, PMID: 20802486

PubMed Abstract | Crossref Full Text | Google Scholar

42. Gopal P, Grüber G, Dartois V, and Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. (2019) 40:930–40. doi: 10.1016/j.tips.2019.10.005, PMID: 31704175

PubMed Abstract | Crossref Full Text | Google Scholar

43. Wayne LG and Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. (1996) 64:2062–9. doi: 10.1128/iai.64.6.2062-2069.1996, PMID: 8675308

PubMed Abstract | Crossref Full Text | Google Scholar

44. Almeida Da Silva PE and Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. (2011) 66:1417–30. doi: 10.1093/jac/dkr173, PMID: 21558086

PubMed Abstract | Crossref Full Text | Google Scholar

45. Hartman TE, Wang Z, Jansen RS, Gardete S, and Rhee KY. Metabolic perspectives on persistence. Microbiol Spectr. (2017) 5. doi: 10.1128/microbiolspec.tbtb2-0026–2016

Crossref Full Text | Google Scholar

46. Chengalroyen MD, Mehaffy C, Lucas M, Bauer N, Raphela ML, Oketade N, et al. Modulation of riboflavin biosynthesis and utilization in mycobacteria. Microbiol Spectr. (2024) 12:e03207–23. doi: 10.1128/spectrum.03207-23, PMID: 38916330

PubMed Abstract | Crossref Full Text | Google Scholar

47. Haase I, Gräwert T, Illarionov B, Bacher A, and Fischer M. Recent advances in riboflavin biosynthesis. In: Weber S and Schleicher E, editors. Flavins and flavoproteins: methods and protocols. Springer, New York, NY (2014). p. 15–40. doi: 10.1007/978-1-4939-0452-5_2, PMID: 24764086

PubMed Abstract | Crossref Full Text | Google Scholar

48. Bair TB, Isabelle DW, and Daniels L. Structures of coenzyme F420 in Mycobacterium species. Arch Microbiol. (2001) 176:37–43. doi: 10.1007/s002030100290, PMID: 11479701

PubMed Abstract | Crossref Full Text | Google Scholar

49. Edwards AM. Structure and general properties of flavins. In: Weber S and Schleicher E, editors. Flavins and flavoproteins: methods and protocols. Springer, New York, NY (2014). p. 3–13. doi: 10.1007/978-1-4939-0452-5_1, PMID: 24764085

PubMed Abstract | Crossref Full Text | Google Scholar

50. Taga ME, Larsen NA, Howard-Jones AR, Walsh CT, and Walker GC. BluB cannibalizes flavin to form the lower ligand of vitamin B12. Nature. (2007) 446:449–53. doi: 10.1038/nature05611, PMID: 17377583

PubMed Abstract | Crossref Full Text | Google Scholar

51. Rifat D, Li SY, Ioerger T, Shah K, Lanoix JP, Lee J, et al.Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrobial Agents Chemotherapy (2020) 65. doi: 10.1128/aac.01948-20, PMID: 33077652

PubMed Abstract | Crossref Full Text | Google Scholar

52. Mascotti ML, Kumar H, Nguyen QT, Ayub MJ, and Fraaije MW. Reconstructing the evolutionary history of F420-dependent dehydrogenases. Sci Rep. (2018) 8:17571. doi: 10.1038/s41598-018-35590-2, PMID: 30514849

PubMed Abstract | Crossref Full Text | Google Scholar

53. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, et al. Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. mBio. (2017) 8. doi: 10.1128/mbio.02133-16, PMID: 28096490

PubMed Abstract | Crossref Full Text | Google Scholar

54. Gurumurthy M, Rao M, Mukherjee T, Rao SPS, Boshoff HI, Dick T, et al. A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol. (2013) 87:744–55. doi: 10.1111/mmi.12127, PMID: 23240649

PubMed Abstract | Crossref Full Text | Google Scholar

55. Selengut JD and Haft DH.Unexpected abundance of coenzyme F420-dependent enzymes in mycobacterium tuberculosis and other actinobacteria. J Bacteriology (2010) 192:5788–98. doi: 10.1128/jb.00425-10?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed, PMID: 20675471

PubMed Abstract | Crossref Full Text | Google Scholar

56. Eckle SBG, Corbett AJ, Keller AN, Chen Z, Godfrey DI, Liu L, et al. Recognition of vitamin B precursors and byproducts by mucosal associated invariant T cells *. J Biol Chem. (2015) 290:30204–11. doi: 10.1074/jbc.R115.685990, PMID: 26468291

PubMed Abstract | Crossref Full Text | Google Scholar

57. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. (2012) 491:717–23. doi: 10.1038/nature11605, PMID: 23051753

PubMed Abstract | Crossref Full Text | Google Scholar

58. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor α Chain defines a novel TAP-independent major histocompatibility complex class ib–restricted α/β T cell subpopulation in mammals. J Exp Med. (1999) 189:1907–21. doi: 10.1084/jem.189.12.1907, PMID: 10377186

PubMed Abstract | Crossref Full Text | Google Scholar

59. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. (2003) 422:164–9. doi: 10.1038/nature01433, PMID: 12634786

PubMed Abstract | Crossref Full Text | Google Scholar

60. Nel I, Bertrand L, Toubal A, and Lehuen A. MAIT cells, guardians of skin and mucosa? Mucosal Immunol. (2021) 14:803–14. doi: 10.1038/s41385-021-00391-w, PMID: 33753874

PubMed Abstract | Crossref Full Text | Google Scholar

61. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. PloS Biol. (2009) 7:e1000054. doi: 10.1371/journal.pbio.1000054, PMID: 19278296

PubMed Abstract | Crossref Full Text | Google Scholar

62. Ussher JE, Klenerman P, and Willberg CB. Mucosal-associated invariant T-cells: new players in anti-bacterial immunity. Front Immunol. (2014) 5:450. doi: 10.3389/fimmu.2014.00450, PMID: 25339949

PubMed Abstract | Crossref Full Text | Google Scholar

63. Sakala IG, Kjer-Nielsen L, Eickhoff CS, Wang X, Blazevic A, Liu L, et al. Functional heterogeneity and antimycobacterial effects of mouse mucosal-associated invariant T cells specific for riboflavin metabolites. J Immunol. (2015) 195:587–601. doi: 10.4049/jimmunol.1402545, PMID: 26063000

PubMed Abstract | Crossref Full Text | Google Scholar

64. Yu H, Yang A, Derrick S, Mak JYW, Liu L, Fairlie DP, et al. Artificially induced MAIT cells inhibit M. bovis BCG but not M. tuberculosis during in vivo pulmonary infection. Sci Rep. (2020) 10:13579. doi: 10.1038/s41598-020-70615-9, PMID: 32788608

PubMed Abstract | Crossref Full Text | Google Scholar

65. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PloS Biol. (2010) 8:e1000407. doi: 10.1371/journal.pbio.1000407, PMID: 20613858

PubMed Abstract | Crossref Full Text | Google Scholar

66. Cross DL, Layton ED, Yu KK, Smith MT, Aguilar MS, Li S, et al. MR1-restricted T cell clonotypes are associated with “resistance” to Mycobacterium tuberculosis infection. JCI Insight. (2024) 9:e166505. doi: 10.1172/jci.insight.166505, PMID: 38716731

PubMed Abstract | Crossref Full Text | Google Scholar

67. Joosten SA, Ottenhoff THM, Lewinsohn DM, Hoft DF, Moody DB, and Seshadri C. Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. Vaccine. (2019) 37:3022–30. doi: 10.1016/j.vaccine.2019.04.050, PMID: 31040086

PubMed Abstract | Crossref Full Text | Google Scholar

68. Boissevain CH, Drea WF, and Schultz HW. Isolation and determination of riboflavin produced by tubercle bacilli in culture media. Proc Soc Exp Biol Med. (1938) 39:481–3. doi: 10.3181/00379727-39-10246

Crossref Full Text | Google Scholar

69. Smith MI and Emmart EW. Studies in the metabolism of the tubercle bacillus: I. The production of riboflavin. J Immunol. (1949) 61:259–69. doi: 10.4049/jimmunol.61.3.259, PMID: 18117863

PubMed Abstract | Crossref Full Text | Google Scholar

70. Mori T, Domae K, and Kohsaka K. Riboflavin in murine leprosy bacillus. Repura. (1964) 33:291–5.

Google Scholar

71. Boissevain CH, Drea WF, and Schultz HW. Isolation and determination of riboflavin produced by tubercle bacilli in culture media. Proc Soc Exp Biol Med. (1938) 39:481–3. doi: 10.3181/00379727-39-10246

Crossref Full Text | Google Scholar

72. Hou HC. Riboflavin and growth of tubercle bacilli. Proc Soc Exp Biol Med. (1949) 70:582–5. doi: 10.3181/00379727-70-17001, PMID: 18149437

PubMed Abstract | Crossref Full Text | Google Scholar

73. Farber JE and Miller DK. Nutritional studies in tuberculosis. Am Rev Tuberc. (1943) 48:406–11.

Google Scholar

74. Bird OD. Vitamin content of tubercle bacilli. Nature. (1947) 159:33–3. doi: 10.1038/159033a0, PMID: 20279073

PubMed Abstract | Crossref Full Text | Google Scholar

75. Purwantini E and Daniels L. Purification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis. J Bacteriol. (1996) 178:2861–6. doi: 10.1128/jb.178.10.2861-2866.1996, PMID: 8631674

PubMed Abstract | Crossref Full Text | Google Scholar

76. Cheeseman P, Toms-Wood A, and Wolfe RS. Isolation and properties of a fluorescent compound, factor 420, from Methanobacterium strain M.o.H. J Bacteriol. (1972) 112:527–31. doi: 10.1128/jb.112.1.527-531.1972, PMID: 5079072

PubMed Abstract | Crossref Full Text | Google Scholar

77. Woese CR, Kandler O, and Wheelis ML. Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya. Proc Natl Acad Sci. (1990) 87:4576–9. doi: 10.1073/pnas.87.12.4576, PMID: 2112744

PubMed Abstract | Crossref Full Text | Google Scholar

78. Koonin EV and Wolf YI. Genomics of bacteria and archaea: the emerging dynamic view of the prokaryotic world. Nucleic Acids Res. (2008) 36:6688–719. doi: 10.1093/nar/gkn668, PMID: 18948295

PubMed Abstract | Crossref Full Text | Google Scholar

79. Naraoka T, Momoi K, Fukasawa K, and Goto M. Isolation and identification of a naturally occurring 7, 8-didemethyl-8-hydroxy-5-deazariboflavin derivative from Mycobacterium avium. Biochim Biophys Acta BBA - Gen Subj. (1984) 797:377–80. https://doi.org/10.1016/0304-4165(84)90260-5

Google Scholar

80. Ney B, Ahmed FH, Carere CR, Biswas A, Warden AC, Morales SE, et al. The methanogenic redox cofactor F420 is widely synthesized by aerobic soil bacteria. ISME J. (2017) 11:125–37. doi: 10.1038/ismej.2016.100, PMID: 27505347

PubMed Abstract | Crossref Full Text | Google Scholar

81. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of mycobacterium tuberculosis. Antimicrob Agents Chemother. (2015) 59:5316–23. doi: 10.1128/AAC.00308-15, PMID: 26100695

PubMed Abstract | Crossref Full Text | Google Scholar

82. Selengut JD and Haft DH. Unexpected abundance of coenzyme F(420)-dependent enzymes in Mycobacterium tuberculosis and other actinobacteria. J Bacteriol. (2010) 192:5788–98. doi: 10.1128/JB.00425-10, PMID: 20675471

PubMed Abstract | Crossref Full Text | Google Scholar

83. Purwantini E and Mukhopadhyay B. Conversion of NO2 to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci. (2009) 106:6333–8. doi: 10.1073/pnas.0812883106, PMID: 19325122

PubMed Abstract | Crossref Full Text | Google Scholar

84. Jirapanjawat T, Ney B, Taylor MC, Warden AC, Afroze S, Russell RJ, et al. The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and mediates a reductive detoxification system. Appl Environ Microbiol. (2016) 82:6810–8. doi: 10.1128/AEM.02500-16, PMID: 27637879

PubMed Abstract | Crossref Full Text | Google Scholar

85. Harriff MJ, McMurtrey C, Froyd CA, Jin H, Cansler M, Null M, et al.MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. Sci Immunol. (2025) 3:eaao2556. doi: 10.1126/sciimmunol.aao2556, PMID: 30006464

PubMed Abstract | Crossref Full Text | Google Scholar

86. Krawic JR, Ladd NA, Cansler M, McMurtrey C, Devereaux J, Worley A, et al. Multiple isomers of photolumazine V bind MR1 and differentially activate MAIT cells. J Immunol. (2024) 212:933–40. doi: 10.4049/jimmunol.2300609, PMID: 38275935

PubMed Abstract | Crossref Full Text | Google Scholar

87. Jin H, Ladd NA, Peev AM, Swarbrick GM, Cansler M, Null M, et al. Deaza-modification of MR1 ligands modulates recognition by MR1-restricted T cells. Sci Rep. (2022) 12:22539. doi: 10.1038/s41598-022-26259-y, PMID: 36581641

PubMed Abstract | Crossref Full Text | Google Scholar

88. Bacher A, Eberhardt S, Fischer M, Kis K, and Richter G. Biosynthesis of vitamin B2 (Riboflavin). Annu Rev Nutr. (2000) 20:153–67. doi: 10.1146/annurev.nutr.20.1.153, PMID: 10940330

PubMed Abstract | Crossref Full Text | Google Scholar

89. Grinter R and Greening C. Cofactor F420: an expanded view of its distribution, biosynthesis and roles in bacteria and archaea. FEMS Microbiol Rev. (2021) 45:fuab021. doi: 10.1093/femsre/fuab021, PMID: 33851978

PubMed Abstract | Crossref Full Text | Google Scholar

90. Greening C, Ahmed FH, Mohamed AE, Lee BM, Pandey G, Warden AC, et al. Physiology, biochemistry, and applications of F420- and fo-dependent redox reactions. Microbiol Mol Biol Rev MMBR. (2016) 80:451–93. doi: 10.1128/MMBR.00070-15, PMID: 27122598

PubMed Abstract | Crossref Full Text | Google Scholar

91. Choi KP, Bair TB, Bae YM, and Daniels L. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J Bacteriol. (2001) 183:7058–66. doi: 10.1128/JB.183.24.7058-7066.2001, PMID: 11717263

PubMed Abstract | Crossref Full Text | Google Scholar

92. Choi KP, Kendrick N, and Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol. (2002) 184:2420–8. doi: 10.1128/JB.184.9.2420-2428.2002, PMID: 11948155

PubMed Abstract | Crossref Full Text | Google Scholar

93. Rifat D, Li SY, Ioerger T, Shah K, Lanoix JP, Lee J, et al. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. (2020) 65:e01948–20. doi: 10.1128/AAC.01948-20, PMID: 33077652

PubMed Abstract | Crossref Full Text | Google Scholar

94. Jaroensuk J, Chuaboon L, Kesornpun C, and Chaiyen P. Enzymes in riboflavin biosynthesis: Potential antibiotic drug targets. Arch Biochem Biophys. (2023) 748:109762. doi: 10.1016/j.abb.2023.109762, PMID: 37739114

PubMed Abstract | Crossref Full Text | Google Scholar

95. Islam Z and Kumar P. Inhibitors of riboflavin biosynthetic pathway enzymes as potential antibacterial drugs. Front Mol Biosci. (2025). doi: 10.3389/fmolb.2023.1228763/fullB88., PMID: 37496776

PubMed Abstract | Crossref Full Text | Google Scholar

96. Sarge S, Haase I, Illarionov B, Laudert D, Hohmann HP, Bacher A, et al. Catalysis of an essential step in vitamin B2 biosynthesis by a consortium of broad spectrum hydrolases. ChemBioChem. (2015) 16:2466–9. doi: 10.1002/cbic.201500352, PMID: 26316208

PubMed Abstract | Crossref Full Text | Google Scholar

97. Kenjić N, Meneely KM, Wherritt DJ, Denler MC, Jackson TA, Moran GR, et al. Evidence for the chemical mechanism of ribB (3,4-dihydroxy-2-butanone 4-phosphate synthase) of riboflavin biosynthesis. J Am Chem Soc. (2022) 144:12769–80. doi: 10.1021/jacs.2c03376, PMID: 35802469

PubMed Abstract | Crossref Full Text | Google Scholar

98. Decamps L, Philmus B, Benjdia A, White R, Begley TP, and Berteau O. Biosynthesis of F0, precursor of the F420 cofactor, requires a unique two radical-SAM domain enzyme and tyrosine as substrate. J Am Chem Soc. (2012) 134:18173–6. doi: 10.1021/ja307762b, PMID: 23072415

PubMed Abstract | Crossref Full Text | Google Scholar

99. Bashiri G, Antoney J, Jirgis ENM, Shah MV, Ney B, Copp J, et al. A revised biosynthetic pathway for the cofactor F420 in prokaryotes. Nat Commun. (2019) 10:1558. doi: 10.1038/s41467-019-09534-x, PMID: 30952857

PubMed Abstract | Crossref Full Text | Google Scholar

100. Bashiri G, Rehan AM, Sreebhavan S, Baker HM, Baker EN, and Squire CJ. Elongation of the poly-γ-glutamate tail of F420 requires both domains of the F420:γ-glutamyl ligase (FbiB) of mycobacterium tuberculosis*. J Biol Chem. (2016) 291:6882–94. doi: 10.1074/jbc.M115.689026, PMID: 26861878

PubMed Abstract | Crossref Full Text | Google Scholar

101. Bresler SE, Cherepenko EI, and Perumov DA. Investigation of the operon of riboflavin biosynthesis in Bacillus subtilis. 3. Production and properties of mutants with a complex regulator genotype. Sov Genet. (1974) 7:1466–70., PMID: 4208212

PubMed Abstract | Google Scholar

102. Vitreschak AG, Rodionov DA, Mironov AA, and Gelfand MS. Regulation of riboflavin biosynthesis and transport genes in bacteria by transcriptional and translational attenuation. Nucleic Acids Res. (2002) 30:3141–51. doi: 10.1093/nar/gkf433, PMID: 12136096

PubMed Abstract | Crossref Full Text | Google Scholar

103. Sun EI, Leyn SA, Kazanov MD, Saier MH, Novichkov PS, and Rodionov DA. Comparative genomics of metabolic capacities of regulons controlled by cis-regulatory RNA motifs in bacteria. BMC Genomics. (2013) 14:597. doi: 10.1186/1471-2164-14-597, PMID: 24060102

PubMed Abstract | Crossref Full Text | Google Scholar

104. Harold LK, Antoney J, Ahmed FH, Hards K, Carr PD, Rapson T, et al. FAD-sequestering proteins protect mycobacteria against hypoxic and oxidative stress. J Biol Chem. (2019) 294:2903–12. doi: 10.1074/jbc.RA118.006237, PMID: 30567740

PubMed Abstract | Crossref Full Text | Google Scholar

105. Bourdeaux F, Hammer CA, Vogt S, Schweighöfer F, Nöll G, Wachtveitl J, et al. Flavin storage and sequestration by mycobacterium tuberculosis dodecin. ACS Infect Dis. (2018) 4:1082–92. doi: 10.1021/acsinfecdis.7b00237, PMID: 29608272

PubMed Abstract | Crossref Full Text | Google Scholar

106. Wolff KA, dela Peña AH, Nguyen HT, Pham TH, Amzel LM, Gabelli SB, et al. A redox regulatory system critical for mycobacterial survival in macrophages and biofilm development. PloS Pathog. (2015) 11:e1004839. doi: 10.1371/journal.ppat.1004839, PMID: 25884716

PubMed Abstract | Crossref Full Text | Google Scholar

107. Macheroux P, Kappes B, and Ealick SE. Flavogenomics – a genomic and structural view of flavin-dependent proteins. FEBS J. (2011) 278:2625–34. doi: 10.1111/j.1742-4658.2011.08202.x, PMID: 21635694

PubMed Abstract | Crossref Full Text | Google Scholar

108. García-Angulo VA. Overlapping riboflavin supply pathways in bacteria. Crit Rev Microbiol. (2017) 43:196–209. doi: 10.1080/1040841X.2016.1192578, PMID: 27822970

PubMed Abstract | Crossref Full Text | Google Scholar

109. Gutiérrez-Preciado A, Torres AG, Merino E, Bonomi HR, Goldbaum FA, and García-Angulo VA. Extensive identification of bacterial riboflavin transporters and their distribution across bacterial species. PloS One. (2015) 10:e0126124. doi: 10.1371/journal.pone.0126124, PMID: 25938806

PubMed Abstract | Crossref Full Text | Google Scholar

110. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. (1998) 393:537–44. doi: 10.1038/31159, PMID: 9634230

PubMed Abstract | Crossref Full Text | Google Scholar

111. Cheng YS and Sacchettini JC. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance. Biochemistry. (2016) 55:1107–19. doi: 10.1021/acs.biochem.5b00993, PMID: 26848874

PubMed Abstract | Crossref Full Text | Google Scholar

112. Gutiérrez-Preciado A, Torres AG, Merino E, Bonomi HR, Goldbaum FA, García-Angulo VA, et al. Extensive identification of bacterial riboflavin transporters and their distribution across bacterial species. PloS One. (2025) 10:e0126124. doi: 10.1371%2Fjournal.pone.0126124&utm_source=chatgpt.compone.0126124.ref019, PMID: 25938806

Google Scholar

113. Bacher A, Eberhardt S, Eisenreich W, Fischer M, Herz S, Illarionov B, et al. Biosynthesis of riboflavin. In: Vitamins & Hormones. Academic Press (2001). p. 1–49. Available online at: https://www.sciencedirect.com/science/article/pii/S008367290161001X (Accessed May 26, 2025).

Google Scholar

114. Singh M, Kumar P, and Karthikeyan S. Structural basis for pH dependent monomer–dimer transition of 3,4-dihydroxy 2-butanone-4-phosphate synthase domain from Mycobacterium tuberculosis. J Struct Biol. (2011) 174:374–84. doi: 10.1016/j.jsb.2011.01.013, PMID: 21296160

PubMed Abstract | Crossref Full Text | Google Scholar

115. Chengalroyen MD, Oketade N, Worley A, Lucas M, Ramirez LN, Raphela ML, et al. Disruption of riboflavin biosynthesis in mycobacteria establishes 5-amino-6-D-ribitylaminouracil (5-A-RU) as key precursor of MAIT cell agonists. PLOS Pathog. (2025) 21:e1012632. doi: 10.1371/journal.ppat.1012632, PMID: 40591719

PubMed Abstract | Crossref Full Text | Google Scholar

116. Suzuki A and Goto M. Photolumazines, new naturally occurring inhibitors of riboflavin synthetase. Biochim Biophys Acta BBA - Gen Subj. (1973) 313:229–34. doi: 10.1016/0304-4165(73)90205-5, PMID: 4355564

PubMed Abstract | Crossref Full Text | Google Scholar

117. Choi KP, Bair TB, Bae YM, and Daniels L. Use of Transposon Tn5367 Mutagenesis and a Nitroimidazopyran-Based Selection System To Demonstrate a Requirement for fbiA and fbiB in Coenzyme F420 Biosynthesis by Mycobacterium bovis BCG. J Bacteriol. (2001) 183:7058–66. doi: 10.1128/JB.183.24.7058-7066.2001, PMID: 11717263

PubMed Abstract | Crossref Full Text | Google Scholar

118. Bashiri G, Rehan AM, Greenwood DR, Dickson JMJ, and Baker EN. Metabolic engineering of cofactor F420 production in mycobacterium smegmatis. PloS One. (2010) 5:e15803. doi: 10.1371/journal.pone.0015803, PMID: 21209917

PubMed Abstract | Crossref Full Text | Google Scholar

119. Wunderer M, Markt R, Prem EM, Peer N, Mullaymeri A, and Wagner AO. Cofactor F420 tail length distribution in different environmental samples. Heliyon. (2024) 10:e39127. doi: 10.1016/j.heliyon.2024.e39127, PMID: 39640720

PubMed Abstract | Crossref Full Text | Google Scholar

120. Ney B, Carere CR, Sparling R, Jirapanjawat T, Stott MB, Jackson CJ, et al. Cofactor tail length modulates catalysis of bacterial F420-dependent oxidoreductases. Front Microbiol. (2017) 8:1902/full. doi: 10.3389/fmicb.2017.01902/full, PMID: 29021791

PubMed Abstract | Crossref Full Text | Google Scholar

121. Purwantini E, Loganathan U, and Mukhopadhyay B. Coenzyme F420-dependent glucose-6-phosphate dehydrogenase-coupled polyglutamylation of coenzyme F420 in mycobacteria. J Bacteriol. (2018) 200:e00375–18. doi: 10.1128/JB.00375-18, PMID: 30249701

PubMed Abstract | Crossref Full Text | Google Scholar

122. Jaenchen R, Schönheit P, and Thauer RK. Studies on the biosynthesis of coenzyme F420 in methanogenic bacteria. Arch Microbiol. (1984) 137:362–5. doi: 10.1007/BF00410735, PMID: 6547290

PubMed Abstract | Crossref Full Text | Google Scholar

123. Graupner M, Xu H, and White RH. Characterization of the 2-phospho-l-lactate transferase enzyme involved in coenzyme F420 biosynthesis in methanococcus jannaschii. Biochemistry. (2002) 41:3754–61. doi: 10.1021/bi011937v, PMID: 11888293

PubMed Abstract | Crossref Full Text | Google Scholar

124. Braga D, Last D, Hasan M, Guo H, Leichnitz D, Uzum Z, et al. Metabolic pathway rerouting in paraburkholderia rhizoxinica evolved long-overlooked derivatives of coenzyme F420. ACS Chem Biol. (2019) 14:2088–94. doi: 10.1021/acschembio.9b00605, PMID: 31469543

PubMed Abstract | Crossref Full Text | Google Scholar

125. Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature. (2014) 509:361–5. doi: 10.1038/nature13160, PMID: 24695216

PubMed Abstract | Crossref Full Text | Google Scholar

126. Gatsios A, Kim CS, York AG, Flavell RA, and Crawford JM. Cellular stress-induced metabolites in escherichia coli. J Nat Prod. (2022) 85:2626–40. doi: 10.1021/acs.jnatprod.2c00706, PMID: 36346625

PubMed Abstract | Crossref Full Text | Google Scholar

127. McNutt WS and Takeda I. Naturally occurring indolylpteridine. Biochemistry. (1969) 8:1370–6. https://doi.org/10.1021/bi00832a010, PMID: 4308720

PubMed Abstract | Google Scholar

128. Adams NE, Thiaville JJ, Proestos J, Juárez-Vázquez AL, McCoy AJ, Barona-Gómez F, et al. Promiscuous and adaptable enzymes fill “Holes” in the tetrahydrofolate pathway in chlamydia species. mBio. (2014) 5. doi: 10.1128/mbio.01378-14, PMID: 25006229

PubMed Abstract | Crossref Full Text | Google Scholar

129. Baughn AD and Rhee KY. Metabolomics of central carbon metabolism in mycobacterium tuberculosis. Microbiol Spectr. (2014) 3). doi: 10.1128/microbiolspec.mgm2-0026–2013, PMID: 26103978

PubMed Abstract | Crossref Full Text | Google Scholar

130. Drapal M and Fraser PD. Metabolite profiling: A tool for the biochemical characterisation of mycobacterium sp. Microorganisms. (2019) 7:148. doi: 10.3390/microorganisms7050148, PMID: 31130621

PubMed Abstract | Crossref Full Text | Google Scholar

131. Visser AJWG and Lee J. Association between lumazine protein and bacterial luciferase: direct demonstration from the decay of the lumazine emission anisotropy. Biochemistry. (1982) 21:2218–26. doi: 10.1021/bi00538a034, PMID: 7093241

PubMed Abstract | Crossref Full Text | Google Scholar

132. Campos-Pardos E, Uranga S, Picó A, Gómez AB, and Gonzalo-Asensio J. Dependency on host vitamin B12 has shaped Mycobacterium tuberculosis Complex evolution. Nat Commun. (2024) 15:2161. doi: 10.1038/s41467-024-46449-8, PMID: 38461302

PubMed Abstract | Crossref Full Text | Google Scholar

133. Izquierdo Lafuente B, Verboom T, Coenraads S, Ummels R, Bitter W, and Speer A. Vitamin B12 uptake across the mycobacterial outer membrane is influenced by membrane permeability in Mycobacterium marinum. Microbiol Spectr. (2024) 12:e03168–23. doi: 10.1128/spectrum.03168-23, PMID: 38722177

PubMed Abstract | Crossref Full Text | Google Scholar

134. Gopinath K, Moosa A, Mizrahi V, and Warner DF. Vitamin B12 metabolism in mycobacterium tuberculosis. Future Microbiol. (2013) 8:1405–18. doi: 10.2217/fmb.13.113, PMID: 24199800

PubMed Abstract | Crossref Full Text | Google Scholar

135. Gelber R, Andries K, Paredes RMD, Andaya CES, and Burgos J. The Diarylquinoline R207910 Is Bactericidal against Mycobacterium leprae in Mice at Low Dose and Administered Intermittently. Antimicrob Agents Chemother. (2009) 53:3989–91. doi: 10.1128/AAC.00722-09, PMID: 19596891

PubMed Abstract | Crossref Full Text | Google Scholar

136. Omar S, Whitfield MG, Nolan MB, Ngom JT, Ismail N, Warren RM, et al. Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis. J Antimicrob Chemother. (2024) 79:211–40. doi: 10.1093/jac/dkad372, PMID: 38134888

PubMed Abstract | Crossref Full Text | Google Scholar

137. Cholo MC, Mothiba MT, Fourie B, and Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. (2017) 72:338–53. doi: 10.1093/jac/dkw426, PMID: 27798208

PubMed Abstract | Crossref Full Text | Google Scholar

138. Bickel MH. The development of sulfonamides (1932-1938) as a focal point in the history of chemotherapy. Gesnerus. (1988) 45:67–86. doi: 10.1163/22977953-04501006, PMID: 3042521

PubMed Abstract | Crossref Full Text | Google Scholar

139. van Miert AS. The sulfonamide-diaminopyrimidine story. J Vet Pharmacol Ther. (1994) 17:309–16. doi: 10.1111/j.1365-2885.1994.tb00251.x, PMID: 7966552

PubMed Abstract | Crossref Full Text | Google Scholar

140. Jortzik E, Wang L, Ma J, and Becker K. Flavins and flavoproteins: applications in medicine. In: Weber S and Schleicher E, editors. Flavins and flavoproteins: methods and protocols. Springer, New York, NY (2014). p. 113–57. doi: 10.1007/978-1-4939-0452-5_7, PMID: 24764091

PubMed Abstract | Crossref Full Text | Google Scholar

141. Liang Y, Plourde A, Bueler SA, Liu J, Brzezinski P, Vahidi S, et al. Structure of mycobacterial respiratory complex I. Proc Natl Acad Sci. (2023) 120:e2214949120. doi: 10.1073/pnas.2214949120, PMID: 36952383

PubMed Abstract | Crossref Full Text | Google Scholar

142. Yano T, Rahimian M, Aneja KK, Schechter NM, Rubin H, and Scott CP. Mycobacterium tuberculosis type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites. Biochemistry. (2014) 53:1179–90. doi: 10.1021/bi4013897, PMID: 24447297

PubMed Abstract | Crossref Full Text | Google Scholar

143. Zhou X, Gao Y, Wang W, Yang X, Yang X, Liu F, et al. Architecture of the mycobacterial succinate dehydrogenase with a membrane-embedded Rieske FeS cluster. Proc Natl Acad Sci. (2021) 118:e2022308118. doi: 10.1073/pnas.2022308118, PMID: 33876763

PubMed Abstract | Crossref Full Text | Google Scholar

144. Gurumurthy M, Rao M, Mukherjee T, Rao SPS, Boshoff HI, Dick T, et al. A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol. (2013) 87:744–55. doi: 10.1111/mmi.12127, PMID: 23240649

PubMed Abstract | Crossref Full Text | Google Scholar

145. Ahmed FH, Carr PD, Lee BM, Afriat-Jurnou L, Mohamed AE, Hong NS, et al. Sequence-structure-function classification of a catalytically diverse oxidoreductase superfamily in mycobacteria. J Mol Biol. (2015) 427:3554–71. doi: 10.1016/j.jmb.2015.09.021, PMID: 26434506

PubMed Abstract | Crossref Full Text | Google Scholar

146. Davis LA, Oyugi MA, Howard J, Corrales J, Aziz A, Mandimutsira C, et al. F420-dependent glucose-6-phosphate dehydrogenase: A comprehensive review. Inorganica Chim Acta. (2021) 524:120417. doi: 10.1016/j.ica.2021.120417

Crossref Full Text | Google Scholar

147. Oyugi MA, Bashiri G, Baker EN, and Johnson-Winters K. Mechanistic Insights into F420-Dependent Glucose-6-Phosphate Dehydrogenase using Isotope Effects and Substrate Inhibition Studies. Biochim Biophys Acta. (2018) 1866:387–95. doi: 10.1016/j.bbapap.2017.08.001, PMID: 28807886

PubMed Abstract | Crossref Full Text | Google Scholar

148. Purwantini E, Daniels L, and Mukhopadhyay B. F420H2 is required for phthiocerol dimycocerosate synthesis in mycobacteria. J Bacteriol. (2016) 198:2020–8. doi: 10.1128/JB.01035-15, PMID: 27185825

PubMed Abstract | Crossref Full Text | Google Scholar

149. Gurumurthy M, Rao M, Mukherjee T, Rao SPS, Boshoff HI, Dick T, et al. A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol. (2013) 87:744–55. doi: 10.1111/mmi.12127, PMID: 23240649

PubMed Abstract | Crossref Full Text | Google Scholar

150. Purwantini E, Gillis TP, and Daniels L. Presence of F420-dependent glucose-6-phosphate dehydrogenase in Mycobacterium and Nocardia species, but absence from Streptomyces and Corynebacterium species and methanogenic Archaea. FEMS Microbiol Lett. (1997) 146:129–34. doi: 10.1111/j.1574-6968.1997.tb10182.x, PMID: 8997717

PubMed Abstract | Crossref Full Text | Google Scholar

151. Taylor MC, Jackson CJ, Tattersall DB, French N, Peat TS, Newman J, et al. Identification and characterization of two families of F420 H2-dependent reductases from Mycobacteria that catalyse aflatoxin degradation. Mol Microbiol. (2010) 78:561–75. doi: 10.1111/j.1365-2958.2010.07356.x, PMID: 20807200

PubMed Abstract | Crossref Full Text | Google Scholar

152. Darwin KH, Ehrt S, Gutierrez-Ramos JC, Weich N, and Nathan CF. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science. (2003) 302:1963–6. doi: 10.1126/science.1091176, PMID: 14671303

PubMed Abstract | Crossref Full Text | Google Scholar

153. Pimviriyakul P and Chaiyen P. Chapter One - Overview of flavin-dependent enzymes. In: Chaiyen P and Tamanoi F, editors. The enzymes. Academic Press (2020). p. 1–36. Available online at: https://www.sciencedirect.com/science/article/pii/S1874604720300226.

Google Scholar

154. Ge SX, Jung D, and Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. (2020) 36:2628–9. doi: 10.1093/bioinformatics/btz931, PMID: 31882993

PubMed Abstract | Crossref Full Text | Google Scholar

155. Pimviriyakul P and Chaiyen P. Chapter One - overview of flavin-dependent enzymes. In: Chaiyen P and Tamanoi F, editors. The Enzymes. Amsterdam: Academic Press (2020) 1–36. Available online at: https://www.sciencedirect.com/science/article/pii/S1874604720300226 (Accessed May 25, 2025).

Google Scholar

156. Gengenbacher M, Rao SPS, Pethe K, and Dick T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiol Read Engl. (2010) 156:81–7. doi: 10.1099/mic.0.033084-0, PMID: 19797356

PubMed Abstract | Crossref Full Text | Google Scholar

157. Perveen S, Pal S, and Sharma R. Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target. RSC Med Chem. (2025) 16:1476–98. doi: 10.1039/D4MD00829D, PMID: 39790127

PubMed Abstract | Crossref Full Text | Google Scholar

158. Beites T, O’Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, et al. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun. (2019) 10:4970. doi: 10.1038/s41467-019-12956-2, PMID: 31672993

PubMed Abstract | Crossref Full Text | Google Scholar

159. Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat Commun. (2016) 7:12393. doi: 10.1038/ncomms12393, PMID: 27506290

PubMed Abstract | Crossref Full Text | Google Scholar

160. Saha P, Kumar M, and Sharma DK. Potential of mycobacterium tuberculosis type II NADH-dehydrogenase in antitubercular drug discovery. ACS Infect Dis. (2025) 11:398–412. doi: 10.1021/acsinfecdis.4c01005, PMID: 39812155

PubMed Abstract | Crossref Full Text | Google Scholar

161. Cook GM, Hards K, Vilchèze C, Hartman T, and Berney M. Energetics of respiration and oxidative phosphorylation in mycobacteria. Microbiol Spectr. (2014) 3). doi: 10.1128/microbiolspec.mgm2-0015–2013, PMID: 25346874

PubMed Abstract | Crossref Full Text | Google Scholar

162. Vilchèze C, Weinrick B, Leung LW, and Jacobs WR. Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence. Proc Natl Acad Sci. (2018) 115:1599–604. doi: 10.1073/pnas.1721545115, PMID: 29382761

PubMed Abstract | Crossref Full Text | Google Scholar

163. Molenaar D, van der Rest ME, Drysch A, and Yücel R. Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of corynebacterium glutamicum. J Bacteriol. (2000) 182:6884–91. doi: 10.1128/JB.182.24.6884-6891.2000, PMID: 11092846

PubMed Abstract | Crossref Full Text | Google Scholar

164. Kumar R, Sharma P, Chauhan A, Singh N, Prajapati VM, and Singh SK. Malate:quinone oxidoreductase knockout makes Mycobacterium tuberculosis susceptible to stress and affects its in vivo survival. Microbes Infect. (2024) 26:105215. doi: 10.1016/j.micinf.2023.105215, PMID: 37689346

PubMed Abstract | Crossref Full Text | Google Scholar

165. Serrano H and Blanchard JS. Kinetic and isotopic characterization of L-proline dehydrogenase from mycobacterium tuberculosis. Biochemistry. (2013) 52:5009–15. doi: 10.1021/bi400338f, PMID: 23834473

PubMed Abstract | Crossref Full Text | Google Scholar

166. Kumar S, Sega S, Lynn-Barbe JK, Harris DL, Koehn JT, Crans DC, et al. Proline dehydrogenase and pyrroline 5 carboxylate dehydrogenase from mycobacterium tuberculosis: evidence for substrate channeling. Pathogens. (2023) 12:1171. doi: 10.3390/pathogens12091171, PMID: 37764979

PubMed Abstract | Crossref Full Text | Google Scholar

167. Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, et al. Virulence of mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe. (2011) 9:21–31. doi: 10.1016/j.chom.2010.12.004, PMID: 21238944

PubMed Abstract | Crossref Full Text | Google Scholar

168. Argyrou A and Blanchard JS. Mycobacterium tuberculosis Lipoamide Dehydrogenase Is Encoded by Rv0462 and Not by the lpdA or lpdB Genes. Biochemistry. (2001) 40:11353–63. doi: 10.1021/bi010575o, PMID: 11560483

PubMed Abstract | Crossref Full Text | Google Scholar

169. Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, et al. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Struct Lond Engl 1993. (2012) 20:101–12. doi: 10.1016/j.str.2011.11.001, PMID: 22244759

PubMed Abstract | Crossref Full Text | Google Scholar

170. Cumming BM, Lamprecht DA, Wells RM, Saini V, Mazorodze JH, and Steyn AJC. The physiology and genetics of oxidative stress in mycobacteria. Microbiol Spectr. (2014) 2. doi: 10.1128/microbiolspec.MGM2-0019-2013, PMID: 26103972

PubMed Abstract | Crossref Full Text | Google Scholar

171. Newton GL, Arnold K, Price MS, Sherrill C, Delcardayre SB, Aharonowitz Y, et al. Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. J Bacteriol. (1996) 178:1990–5. doi: 10.1128/jb.178.7.1990-1995.1996, PMID: 8606174

PubMed Abstract | Crossref Full Text | Google Scholar

172. Van Laer K, Buts L, Foloppe N, Vertommen D, Van Belle K, Wahni K, et al. Mycoredoxin-1 is one of the missing links in the oxidative stress defence mechanism of Mycobacteria. Mol Microbiol. (2012) 86:787–804. doi: 10.1111/mmi.12030, PMID: 22970802

PubMed Abstract | Crossref Full Text | Google Scholar

173. Gattis SG and Palfey BA. Direct observation of the participation of flavin in product formation by thyX-encoded thymidylate synthase. J Am Chem Soc. (2005) 127:832–3. doi: 10.1021/ja0432214, PMID: 15656610

PubMed Abstract | Crossref Full Text | Google Scholar

174. Tanweer S, Sharma T, Grover A, Agarwal M, and Grover S. Mycobacterium tuberculosis Essential Gene Thymidylate Synthase Is Involved in Immune Modulation and Survival inside the Host. ACS Omega. (2024) 9:33743–50. doi: 10.1021/acsomega.4c02919, PMID: 39130601

PubMed Abstract | Crossref Full Text | Google Scholar

175. Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, et al. Virulence of mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe. (2011) 9:21–31. doi: 10.1016/j.chom.2010.12.004, PMID: 21238944

PubMed Abstract | Crossref Full Text | Google Scholar

176. Mestre O, Hurtado-Ortiz R, Vultos TD, Namouchi A, Cimino M, Pimentel M, et al. High throughput phenotypic selection of mycobacterium tuberculosis mutants with impaired resistance to reactive oxygen species identifies genes important for intracellular growth. PloS One. (2013) 8:e53486. doi: 10.1371/journal.pone.0053486, PMID: 23320090

PubMed Abstract | Crossref Full Text | Google Scholar

177. Hasan MR, Rahman M, Jaques S, Purwantini E, and Daniels L. Glucose 6-Phosphate Accumulation in Mycobacteria: Implications for a novel f420-dependent anti-oxidant defense system. J Biol Chem. (2010) 285:19135–44. doi: 10.1074/jbc.M109.074310, PMID: 20075070

PubMed Abstract | Crossref Full Text | Google Scholar

178. Baughn AD and Rhee KY. Metabolomics of central carbon metabolism in mycobacterium tuberculosis. Microbiol Spectr. (2014) 3). doi: 10.1128/microbiolspec.mgm2-0026–2013, PMID: 26103978

PubMed Abstract | Crossref Full Text | Google Scholar

179. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, Mckinney JD, Bertozzi CR, et al. Cholesterol catabolism by mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol. (2012) 19:218–27. doi: 10.1016/j.chembiol.2011.12.016, PMID: 22365605

PubMed Abstract | Crossref Full Text | Google Scholar

180. De Carvalho LPS, Fischer SM, Marrero J, Nathan C, Ehrt S, and Rhee KY. Metabolomics of mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol. (2010) 17:1122–31. doi: 10.1016/j.chembiol.2010.08.009, PMID: 21035735

PubMed Abstract | Crossref Full Text | Google Scholar

181. Eoh H and Rhee KY. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc Natl Acad Sci. (2013) 110:6554–9. doi: 10.1073/pnas.1219375110, PMID: 23576728

PubMed Abstract | Crossref Full Text | Google Scholar

182. Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, et al. Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multi-enzyme complexes. Cell Host Microbe. (2011) 9:21–31. doi: 10.1016/j.chom.2010.12.004, PMID: 21238944

PubMed Abstract | Crossref Full Text | Google Scholar

183. Billig S, Schneefeld M, Huber C, Grassl GA, Eisenreich W, and Bange FC. Lactate oxidation facilitates growth of Mycobacterium tuberculosis in human macrophages. Sci Rep. (2017) 7:6484. doi: 10.1038/s41598-017-05916-7, PMID: 28744015

PubMed Abstract | Crossref Full Text | Google Scholar

184. Stanley S, Wang X, Liu Q, Kwon YY, Frey AM, Hicks ND, et al. Ongoing evolution of the Mycobacterium tuberculosis lactate dehydrogenase reveals the pleiotropic effects of bacterial adaption to host pressure. PloS Pathog. (2024) 20:e1012050. doi: 10.1371/journal.ppat.1012050, PMID: 38422159

PubMed Abstract | Crossref Full Text | Google Scholar

185. Pandey AK and Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci. (2008) 105:4376–80. doi: 10.1073/pnas.0711159105, PMID: 18334639

PubMed Abstract | Crossref Full Text | Google Scholar

186. Wilburn KM, Fieweger RA, and VanderVen BC. Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis. Pathog Dis. (2018) 76:fty021. doi: 10.1093/femspd/fty021, PMID: 29718271

PubMed Abstract | Crossref Full Text | Google Scholar

187. Vander Beken S, Al Dulayymi JR, Naessens T, Koza G, Maza-Iglesias M, Rowles R, et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur J Immunol. (2011) 41:450–60. doi: 10.1002/eji.201040719, PMID: 21268014

PubMed Abstract | Crossref Full Text | Google Scholar

188. Quadri LEN. Biosynthesis of mycobacterial lipids by polyketide synthases and beyond. Crit Rev Biochem Mol Biol. (2014) 49:179–211. doi: 10.3109/10409238.2014.896859, PMID: 24625105

PubMed Abstract | Crossref Full Text | Google Scholar

189. Beites T, Jansen RS, Wang R, Jinich A, Rhee KY, Schnappinger D, et al. Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection. Nat Commun. (2021) 12:6593. doi: 10.1038/s41467-021-26941-1, PMID: 34782606

PubMed Abstract | Crossref Full Text | Google Scholar

190. Arshad K, Salim J, Talat MA, Ashraf A, and Kanwal N. Integrated virtual screening and MD simulation study to discover potential inhibitors of mycobacterial electron transfer flavoprotein oxidoreductase. PloS One. (2024) 19:e0312860. doi: 10.1371/journal.pone.0312860, PMID: 39546486

PubMed Abstract | Crossref Full Text | Google Scholar

191. Elad N, Baron S, Peleg Y, Albeck S, Grunwald J, Raviv G, et al. Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution. Nat Commun. (2018) 9:3886. doi: 10.1038/s41467-018-06440-6, PMID: 30250274

PubMed Abstract | Crossref Full Text | Google Scholar

192. Bhatt A, Molle V, Besra GS, Jacobs WR, and Kremer L. The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. Mol Microbiol. (2007) 64:1442–54. doi: 10.1111/j.1365-2958.2007.05761.x, PMID: 17555433

PubMed Abstract | Crossref Full Text | Google Scholar

193. Mittal E, Prasad GVRK, Upadhyay S, Sadadiwala J, Olive AJ, Yang G, et al. Mycobacterium tuberculosis virulence lipid PDIM inhibits autophagy in mice. Nat Microbiol. (2024) 9:2970–84. doi: 10.1038/s41564-024-01797-5, PMID: 39242815

PubMed Abstract | Crossref Full Text | Google Scholar

194. Quigley J, Hughitt VK, Velikovsky CA, Mariuzza RA, El-Sayed NM, and Briken V. The cell wall lipid PDIM contributes to phagosomal escape and host cell exit of mycobacterium tuberculosis. mBio. (2017) 8. doi: 10.1128/mbio.00148-17, PMID: 28270579

PubMed Abstract | Crossref Full Text | Google Scholar

195. Purwantini E, Daniels L, and Mukhopadhyay B. F420H2 is required for phthiocerol dimycocerosate synthesis in mycobacteria. J Bacteriol. (2016) 198:2020–8. doi: 10.1128/JB.01035-15, PMID: 27185825

PubMed Abstract | Crossref Full Text | Google Scholar

196. Purwantini E and Mukhopadhyay B. Rv0132c of mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase. PloS One. (2013) 8:e81985. doi: 10.1371/journal.pone.0081985, PMID: 24349169

PubMed Abstract | Crossref Full Text | Google Scholar

197. Grigg JC, Copp JN, Krekhno JMC, Liu J, Ibrahimova A, and Eltis LD. Deciphering the biosynthesis of a novel lipid in Mycobacterium tuberculosis expands the known roles of the nitroreductase superfamily. J Biol Chem. (2023) 299. doi: 10.1016/j.jbc.2023.104924, PMID: 37328106

PubMed Abstract | Crossref Full Text | Google Scholar

198. Rudra P, Hurst-Hess K, Lappierre P, and Ghosh P. High levels of intrinsic tetracycline resistance in mycobacterium abscessus are conferred by a tetracycline-modifying monooxygenase. Antimicrob Agents Chemother. (2018) 62:e00119–18. doi: 10.1128/AAC.00119-18, PMID: 29632012

PubMed Abstract | Crossref Full Text | Google Scholar

199. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro ALDJL, et al. Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Mol Microbiol. (2010) 77:1172–85. doi: 10.1111/j.1365-2958.2010.07277.x, PMID: 20624223

PubMed Abstract | Crossref Full Text | Google Scholar

200. Jirapanjawat T, Ney B, Taylor MC, Warden AC, Afroze S, Russell RJ, et al. The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and mediates a reductive detoxification system. Appl Environ Microbiol. (2016) 82:6810–8. doi: 10.1128/AEM.02500-16, PMID: 27637879

PubMed Abstract | Crossref Full Text | Google Scholar

201. Greening C, Jirapanjawat T, Afroze S, Ney B, Scott C, Pandey G, et al. Mycobacterial F420H2-dependent reductases promiscuously reduce diverse compounds through a common mechanism. Front Microbiol. (2017) 8:1000/full. doi: 10.3389/fmicb.2017.01000/full, PMID: 28620367

PubMed Abstract | Crossref Full Text | Google Scholar

202. Ahmed FH, Carr PD, Lee BM, Afriat-Jurnou L, Mohamed AE, Hong NS, et al. Sequence–structure–function classification of a catalytically diverse oxidoreductase superfamily in mycobacteria. J Mol Biol. (2015) 427:3554–71. doi: 10.1016/j.jmb.2015.09.021, PMID: 26434506

PubMed Abstract | Crossref Full Text | Google Scholar

203. Bartek IL, Rutherford R, Gruppo V, Morton RA, Morris RP, Klein MR, et al. The DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis. (2009) 89:310–6. doi: 10.1016/j.tube.2009.06.001, PMID: 19577518

PubMed Abstract | Crossref Full Text | Google Scholar

204. Heng Y, Seah PG, Siew JY, Tay HC, Singhal A, Mathys V, et al. Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis. (2011) 91:339–41. doi: 10.1016/j.tube.2011.05.003, PMID: 21636324

PubMed Abstract | Crossref Full Text | Google Scholar

205. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, and Dick T. Oxygen depletion-induced dormancy in mycobacterium bovis BCG. J Bacteriol. (1999) 181:2252–6. doi: 10.1128/JB.181.7.2252-2256.1999, PMID: 10094705

PubMed Abstract | Crossref Full Text | Google Scholar

206. Aly S, Wagner K, Keller C, Malm S, Malzan A, Brandau S, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol. (2006) 210:298–305. doi: 10.1002/path.2055, PMID: 17001607

PubMed Abstract | Crossref Full Text | Google Scholar

207. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, et al. Tuberculous granulomas are hypoxic in Guinea pigs, rabbits, and nonhuman primates. Infect Immun. (2008) 76:2333–40. doi: 10.1128/IAI.01515-07, PMID: 18347040

PubMed Abstract | Crossref Full Text | Google Scholar

208. Kendall SL, Movahedzadeh F, Rison SCG, Wernisch L, Parish T, Duncan K, et al. The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses. Tuberculosis. (2004) 84:247–55. doi: 10.1016/j.tube.2003.12.007, PMID: 15207494

PubMed Abstract | Crossref Full Text | Google Scholar

209. Honaker RW, Leistikow RL, Bartek IL, and Voskuil MI. Unique roles of dosT and dosS in dosR regulon induction and mycobacterium tuberculosis dormancy. Infect Immun. (2009) 77:3258–63. doi: 10.1128/IAI.01449-08, PMID: 19487478

PubMed Abstract | Crossref Full Text | Google Scholar

210. Chen T, He L, Deng W, and Xie J. The Mycobacterium DosR regulon structure and diversity revealed by comparative genomic analysis. J Cell Biochem. (2013) 114:1–6. doi: 10.1002/jcb.24302, PMID: 22833514

PubMed Abstract | Crossref Full Text | Google Scholar

211. Cho HY, Cho HJ, Kim YM, Oh JI, and Kang BS. Structural Insight into the Heme-based Redox Sensing by DosS from Mycobacterium tuberculosis*. J Biol Chem. (2009) 284:13057–67. doi: 10.1074/jbc.M808905200, PMID: 19276084

PubMed Abstract | Crossref Full Text | Google Scholar

212. Chauviac FX, Bommer M, Yan J, Parkin G, Daviter T, Lowden P, et al. Crystal Structure of Reduced MsAcg, a Putative Nitroreductase from Mycobacterium smegmatis and a Close Homologue of Mycobacterium tuberculosis Acg. J Biol Chem. (2012) 287:44372–83. doi: 10.1074/jbc.M112.406264, PMID: 23148223

PubMed Abstract | Crossref Full Text | Google Scholar

213. Anoz-Carbonell E, Rivero M, Polo V, Velázquez-Campoy A, and Medina M. Human riboflavin kinase: Species-specific traits in the biosynthesis of the FMN cofactor. FASEB J. (2020) 34:10871–86. doi: 10.1096/fj.202000566R, PMID: 32649804

PubMed Abstract | Crossref Full Text | Google Scholar

214. Huerta C, Borek D, Machius M, Grishin NV, and Zhang H. Structure and mechanism of a eukaryotic FMN adenylyltransferase. J Mol Biol. (2009) 389:388–400. doi: 10.1016/j.jmb.2009.04.022, PMID: 19375431

PubMed Abstract | Crossref Full Text | Google Scholar

215. Cushman M, Jin G, Illarionov B, Fischer M, Ladenstein R, and Bacher A. Design, synthesis, and biochemical evaluation of 1,5,6,7-tetrahydro-6,7-dioxo-9-D-ribitylaminolumazines bearing alkyl phosphate substituents as inhibitors of lumazine synthase and riboflavin synthase. J Org Chem. (2005) 70:8162–70. doi: 10.1021/jo051332v, PMID: 16277343

PubMed Abstract | Crossref Full Text | Google Scholar

216. Cushman M, Mavandadi F, Kugelbrey K, and Bacher A. Synthesis of 2,6-Dioxo-(1H,3H)-9-N-ribitylpurine and 2,6-Dioxo-(1H,3H)-8-aza-9-N-ribitylpurine as inhibitors of lumazine synthase and riboflavin synthase. Bioorg Med Chem. (1998) 6:409–15. doi: 10.1016/S0968-0896(98)00013-3, PMID: 9597185

PubMed Abstract | Crossref Full Text | Google Scholar

217. Cushman M, Yang D, Kis K, and Bacher A. Design, synthesis, and evaluation of 9-d-ribityl-1,3,7-trihydro-2,6,8-purinetrione, a potent inhibitor of riboflavin synthase and lumazine synthase. J Org Chem. (2001) 66:8320–7. doi: 10.1021/jo010706r, PMID: 11735509

PubMed Abstract | Crossref Full Text | Google Scholar

218. Cushman M, Yang D, Gerhardt S, Huber R, Fischer M, Kis K, et al. Design, synthesis, and evaluation of 6-carboxyalkyl and 6-phosphonoxyalkyl derivatives of 7-oxo-8-ribitylaminolumazines as inhibitors of riboflavin synthase and lumazine synthase. J Org Chem. (2002) 67:5807–16. doi: 10.1021/jo0201631, PMID: 12153285

PubMed Abstract | Crossref Full Text | Google Scholar

219. Harale B, Kidwai S, Ojha D, Singh M, Chouhan DK, Singh R, et al. Synthesis and evaluation of antimycobacterial activity of riboflavin derivatives. Bioorg Med Chem Lett. (2021) 48:128236. doi: 10.1016/j.bmcl.2021.128236, PMID: 34242760

PubMed Abstract | Crossref Full Text | Google Scholar

220. Talukdar A, Illarionov B, Bacher A, Fischer M, and Cushman M. Synthesis and enzyme inhibitory activity of the S-nucleoside analogue of the ribitylaminopyrimidine substrate of lumazine synthase and product of riboflavin synthase. J Org Chem. (2007) 72:7167–75. doi: 10.1021/jo0709495, PMID: 17696548

PubMed Abstract | Crossref Full Text | Google Scholar

221. Talukdar A, Zhao Y, Lv W, Bacher A, Illarionov B, Fischer M, et al. O-nucleoside, S-nucleoside, and N-nucleoside probes of lumazine synthase and riboflavin synthase. J Org Chem. (2012) 77:6239–61. doi: 10.1021/jo3010364, PMID: 22780198

PubMed Abstract | Crossref Full Text | Google Scholar

222. Zhang Y, Illarionov B, Morgunova E, Jin G, Bacher A, Fischer M, et al. A new series of N-[2,4-dioxo-6-d-ribitylamino-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid derivatives as inhibitors of lumazine synthase and riboflavin synthase:  Design, synthesis, biochemical evaluation, crystallography, and mechanistic implications. J Org Chem. (2008) 73:2715–24. doi: 10.1021/jo702631a, PMID: 18331058

PubMed Abstract | Crossref Full Text | Google Scholar

223. Zhang Y, Jin G, Illarionov B, Bacher A, Fischer M, and Cushman M. A new series of 3-alkyl phosphate derivatives of 4,5,6,7-tetrahydro-1-d-ribityl-1H-pyrazolo[3,4-d]pyrimidinedione as inhibitors of lumazine synthase:  Design, synthesis, and evaluation. J Org Chem. (2007) 72:7176–84. doi: 10.1021/jo070982r, PMID: 17705537

PubMed Abstract | Crossref Full Text | Google Scholar

224. Cushman M, Sambaiah T, Jin G, Illarionov B, Fischer M, and Bacher A. Design, synthesis, and evaluation of 9-d-ribitylamino-1,3,7,9-tetrahydro-2,6,8-purinetriones bearing alkyl phosphate and α,α-difluorophosphonate substituents as inhibitors of riboflavin synthase and lumazine synthase. J Org Chem. (2004) 69:601–12. doi: 10.1021/jo030278k, PMID: 14750781

PubMed Abstract | Crossref Full Text | Google Scholar

225. Morgunova E, Meining W, Illarionov B, Haase I, Jin G, Bacher A, et al. Crystal structure of lumazine synthase from mycobacterium tuberculosis as a target for rational drug design:  Binding mode of a new class of purinetrione inhibitors. Biochemistry. (2005) 44:2746–58. doi: 10.1021/bi047848a, PMID: 15723519

PubMed Abstract | Crossref Full Text | Google Scholar

226. Talukdar A, Morgunova E, Duan J, Meining W, Foloppe N, Nilsson L, et al. Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase. Bioorg Med Chem. (2010) 18:3518–34. doi: 10.1016/j.bmc.2010.03.072, PMID: 20430628

PubMed Abstract | Crossref Full Text | Google Scholar

227. Singh M, Dhanwal A, Verma A, Augustin L, Kumari N, Chakraborti S, et al. Discovery of potent antimycobacterial agents targeting lumazine synthase (RibH) of Mycobacterium tuberculosis. Sci Rep. (2024) 14:12170. doi: 10.1038/s41598-024-63051-6, PMID: 38806590

PubMed Abstract | Crossref Full Text | Google Scholar

228. Morgunova E, Illarionov B, Sambaiah T, Haase I, Bacher A, Cushman M, et al. Structural and thermodynamic insights into the binding mode of five novel inhibitors of lumazine synthase from Mycobacterium tuberculosis. FEBS J. (2006) 273:4790–804. doi: 10.1111/j.1742-4658.2006.05481.x, PMID: 16984393

PubMed Abstract | Crossref Full Text | Google Scholar

229. Chen J, Illarionov B, Bacher A, Fischer M, Haase I, Georg G, et al. A high-throughput screen utilizing the fluorescence of riboflavin for identification of lumazine synthase inhibitors. Anal Biochem. (2005) 338:124–30. doi: 10.1016/j.ab.2004.11.033, PMID: 15707942

PubMed Abstract | Crossref Full Text | Google Scholar

230. Talukdar A, Breen M, Bacher A, Illarionov B, Fischer M, Georg G, et al. Discovery and development of a small molecule library with lumazine synthase inhibitory activity. J Org Chem. (2009) 74:5123–34. doi: 10.1021/jo900238q, PMID: 19552377

PubMed Abstract | Crossref Full Text | Google Scholar

231. Haase I, Gräwert T, Illarionov B, Bacher A, and Fischer M. Recent advances in riboflavin biosynthesis. In: Weber S and Schleicher E, editors. Flavins and flavoproteins: methods and protocols. Springer, New York, NY (2014). p. 15–40. doi: 10.1007/978-1-4939-0452-5_2, PMID: 24764086

PubMed Abstract | Crossref Full Text | Google Scholar

232. Kaiser J, Illarionov B, Rohdich F, Eisenreich W, Saller S, den Brulle JV, et al. A high-throughput screening platform for inhibitors of the riboflavin biosynthesis pathway. Anal Biochem. (2007) 365:52–61. doi: 10.1016/j.ab.2007.02.033, PMID: 17400171

PubMed Abstract | Crossref Full Text | Google Scholar

233. Zhao Y, Bacher A, Illarionov B, Fischer M, Georg G, Ye QZ, et al. Discovery and development of the covalent hydrates of trifluoromethylated pyrazoles as riboflavin synthase inhibitors with antibiotic activity against mycobacterium tuberculosis. J Org Chem. (2009) 74:5297–303. doi: 10.1021/jo900768c, PMID: 19545132

PubMed Abstract | Crossref Full Text | Google Scholar

234. Serer MI, Carrica M del C, Trappe J, López Romero S, Bonomi HR, Klinke S, et al. A high-throughput screening for inhibitors of riboflavin synthase identifies novel antimicrobial compounds to treat brucellosis. FEBS J. (2019) 286:2522–35. doi: 10.1111/febs.14829, PMID: 30927485

PubMed Abstract | Crossref Full Text | Google Scholar

235. Otani S, Takatsu M, Nakano M, Kasai S, and Miura R. Letter: Roseoflavin, a new antimicrobial pigment from Streptomyces. J Antibiot (Tokyo). (1974) 27:86–7. https://doi.org/10.7164/antibiotics.27.86, PMID: 4843053

PubMed Abstract | Google Scholar

236. Lee ER, Blount KF, and Breaker RR. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol. (2009) 6:187–94. doi: 10.4161/rna.6.2.7727, PMID: 19246992

PubMed Abstract | Crossref Full Text | Google Scholar

237. Harale B, Kidwai S, Ojha D, Singh M, Chouhan DK, Singh R, et al. Synthesis and evaluation of antimycobacterial activity of riboflavin derivatives. Bioorg Med Chem Lett. (2021) 48:128236. doi: 10.1016/j.bmcl.2021.128236, PMID: 34242760

PubMed Abstract | Crossref Full Text | Google Scholar

238. Langer S, Hashimoto M, Hobl B, Mathes T, and Mack M. Flavoproteins are potential targets for the antibiotic roseoflavin in escherichia coli. J Bacteriol. (2013) 195:4037–45. doi: 10.1128/JB.00646-13, PMID: 23836860

PubMed Abstract | Crossref Full Text | Google Scholar

239. Howe JA, Wang H, Fischmann TO, Balibar CJ, Xiao L, Galgoci AM, et al. Selective small-molecule inhibition of an RNA structural element. Nature. (2015) 526:672–7. doi: 10.1038/nature15542, PMID: 26416753

PubMed Abstract | Crossref Full Text | Google Scholar

240. Blount KF, Megyola C, Plummer M, Osterman D, O’Connell T, Aristoff P, et al. Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora. Antimicrob Agents Chemother. (2015) 59:5736–46. doi: 10.1128/AAC.01282-15, PMID: 26169403

PubMed Abstract | Crossref Full Text | Google Scholar

241. Massey V, Strickland S, Mayhew SG, Howell LG, Engel PC, Matthews RG, et al. The production of superoxide anion radicals in the reaction of reduced flavins and flavoproteins with molecular oxygen. Biochem Biophys Res Commun. (1969) 36:891–7. doi: 10.1016/0006-291X(69)90287-3, PMID: 5388670

PubMed Abstract | Crossref Full Text | Google Scholar

242. Grininger M, Staudt H, Johansson P, Wachtveitl J, and Oesterhelt D. Dodecin is the key player in flavin homeostasis of archaea. J Biol Chem. (2009) 284:13068–76. doi: 10.1074/jbc.M808063200, PMID: 19224924

PubMed Abstract | Crossref Full Text | Google Scholar

243. Liu F, Xiong J, Kumar S, Yang C, Ge S, Li S, et al. Structural and biophysical characterization of Mycobacterium tuberculosis dodecin Rv1498A. J Struct Biol. (2011) 175:31–8. doi: 10.1016/j.jsb.2011.04.013, PMID: 21539921

PubMed Abstract | Crossref Full Text | Google Scholar

244. Harold LK, Antoney J, Ahmed FH, Hards K, Carr PD, Rapson T, et al. FAD-sequestering proteins protect mycobacteria against hypoxic and oxidative stress. J Biol Chem. (2019) 294:2903–5814. doi: 10.1074/jbc.RA118.006237, PMID: 30567740

PubMed Abstract | Crossref Full Text | Google Scholar

245. Purkayastha A, McCue LA, and McDonough KA. Identification of a Mycobacterium tuberculosis Putative Classical Nitroreductase Gene Whose Expression Is Coregulated with That of the acr Gene within Macrophages, in Standing versus Shaking Cultures, and under Low Oxygen Conditions. Infect Immun. (2002) 70:1518–29. doi: 10.1128/IAI.70.3.1518-1529.2002, PMID: 11854240

PubMed Abstract | Crossref Full Text | Google Scholar

246. Chauviac FX, Bommer M, Yan J, Parkin G, Daviter T, Lowden P, et al. Crystal Structure of Reduced MsAcg, a Putative Nitroreductase from Mycobacterium smegmatis and a Close Homologue of Mycobacterium tuberculosis Acg. J Biol Chem. (2012) 287:44372–83. doi: 10.1074/jbc.M112.406264, PMID: 23148223

PubMed Abstract | Crossref Full Text | Google Scholar

247. Hu Y and Coates ARM. Mycobacterium tuberculosis acg Gene Is Required for Growth and Virulence In Vivo. PloS One. (2011) 6:e20958. doi: 10.1371/journal.pone.0020958, PMID: 21687631

PubMed Abstract | Crossref Full Text | Google Scholar

248. Griffin JE, Gawronski JD, DeJesus MA, Ioerger TR, Akerley BJ, and Sassetti CM. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PloS Pathog. (2011) 7:e1002251. doi: 10.1371/journal.ppat.1002251, PMID: 21980284

PubMed Abstract | Crossref Full Text | Google Scholar

249. Schubert OT, Ludwig C, Kogadeeva M, Zimmermann M, Rosenberger G, Gengenbacher M, et al. Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis. Cell Host Microbe. (2015) 18:96–108. doi: 10.1016/j.chom.2015.06.001, PMID: 26094805

PubMed Abstract | Crossref Full Text | Google Scholar

250. Rohde KH, Abramovitch RB, and Russell DG. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe. (2007) 2:352–64. doi: 10.1016/j.chom.2007.09.006, PMID: 18005756

PubMed Abstract | Crossref Full Text | Google Scholar

251. Oketade N and Dobos KM. Proteomic insights into mycobacterial responses to elevated riboflavin reveal a role for flavin-sequestering proteins in flavin homeostasis. Front Tuberc. (2025) 3:1719707/full. doi: 10.3389/ftubr.2025.1719707/full

Crossref Full Text | Google Scholar

252. Ahmed FH, Carr PD, Lee BM, Afriat-Jurnou L, Mohamed AE, Hong NS, et al. Sequence–structure–function classification of a catalytically diverse oxidoreductase superfamily in mycobacteria. J Mol Biol. (2015) 427:3554–71. doi: 10.1016/j.jmb.2015.09.021, PMID: 26434506

PubMed Abstract | Crossref Full Text | Google Scholar

253. North RJ. Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol. (1973) 7:166–76. doi: 10.1016/0008-8749(73)90193-7, PMID: 4540430

PubMed Abstract | Crossref Full Text | Google Scholar

254. Behar SM, Dascher CC, Grusby MJ, Wang CR, and Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with mycobacterium tuberculosis. J Exp Med. (1999) 189:1973–80. doi: 10.1084/jem.189.12.1973, PMID: 10377193

PubMed Abstract | Crossref Full Text | Google Scholar

255. Layre E, Collmann A, Bastian M, Mariotti S, Czaplicki J, Prandi J, et al. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. Chem Biol. (2009) 16:82–92. doi: 10.1016/j.chembiol.2008.11.008, PMID: 19171308

PubMed Abstract | Crossref Full Text | Google Scholar

256. Chen ZW. Immune regulation of γδ T cell responses in mycobacterial infections. Clin Immunol Orlando Fla. (2005) 116:202–7. doi: 10.1016/j.clim.2005.04.005, PMID: 16087145

PubMed Abstract | Crossref Full Text | Google Scholar

257. Seshadri C, Thuong NTT, Mai NTH, Bang ND, Chau TTH, Lewinsohn DM, et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. Genes Immun. (2017) 18:8–14. doi: 10.1038/gene.2016.41, PMID: 27881839

PubMed Abstract | Crossref Full Text | Google Scholar

258. Harriff MJ, McMurtrey C, Froyd CA, Jin H, Cansler M, Null M, et al. MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. Sci Immunol. (2018) 3:eaao2556. doi: 10.1126/sciimmunol.aao2556, PMID: 30006464

PubMed Abstract | Crossref Full Text | Google Scholar

259. Joosten SA, Ottenhoff THM, Lewinsohn DM, Hoft DF, Moody DB, and Seshadri C. Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. Vaccine. (2019) 37:3022–30. doi: 10.1016/j.vaccine.2019.04.050, PMID: 31040086

PubMed Abstract | Crossref Full Text | Google Scholar

260. Le Bourhis L, Martin E, Péguillet I, Guihot A, Froux N, Coré M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol. (2010) 11:701–8. doi: 10.1038/ni.1890, PMID: 20581831

PubMed Abstract | Crossref Full Text | Google Scholar

261. McInerney MP, Awad W, Souter MNT, Kang Y, Wang CJH, Chan Yew Poa K, et al. MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells. Proc Natl Acad Sci. (2024) 121:e2414792121. doi: 10.1073/pnas.2414792121, PMID: 39589872

PubMed Abstract | Crossref Full Text | Google Scholar

262. Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, et al. MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci. (2009) 106:8290–5. doi: 10.1073/pnas.0903196106, PMID: 19416870

PubMed Abstract | Crossref Full Text | Google Scholar

263. Yamaguchi H, Hirai M, Kurosawa Y, and Hashimoto K. A highly conserved major histocompatibility complex class I-related gene in mammals. Biochem Biophys Res Commun. (1997) 238:697–702. doi: 10.1006/bbrc.1997.7379, PMID: 9325151

PubMed Abstract | Crossref Full Text | Google Scholar

264. Ciacchi L, Mak JYW, Le JP, Fairlie DP, McCluskey J, Corbett AJ, et al. Mouse mucosal-associated invariant T cell receptor recognition of MR1 presenting the vitamin B metabolite, 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil. J Biol Chem. (2024) 300. doi: 10.1016/j.jbc.2024.107229, PMID: 38537698

PubMed Abstract | Crossref Full Text | Google Scholar

265. Porcelli S, Yockey CE, Brenner MB, and Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med. (1993) 178:1–16. doi: 10.1084/jem.178.1.1, PMID: 8391057

PubMed Abstract | Crossref Full Text | Google Scholar

266. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. (2003) 422:164–9. doi: 10.1038/nature01433, PMID: 12634786

PubMed Abstract | Crossref Full Text | Google Scholar

267. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med. (2013) 210:2305–20. doi: 10.1084/jem.20130958, PMID: 24101382

PubMed Abstract | Crossref Full Text | Google Scholar

268. Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, Tschumi A, et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat Commun. (2014) 5:3866. doi: 10.1038/ncomms4866, PMID: 24832684

PubMed Abstract | Crossref Full Text | Google Scholar

269. Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM, et al. Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood. (2012) 119:422–33. doi: 10.1182/blood-2011-05-353789, PMID: 22086415

PubMed Abstract | Crossref Full Text | Google Scholar

270. Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R, et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. (2014) 9:1075–88. doi: 10.1016/j.celrep.2014.09.045, PMID: 25437561

PubMed Abstract | Crossref Full Text | Google Scholar

271. Sharma PK, Wong EB, Napier RJ, Bishai WR, Ndung’u T, Kasprowicz VO, et al. High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells. Immunology. (2015) 145:443–53. doi: 10.1111/imm.12461, PMID: 25752900

PubMed Abstract | Crossref Full Text | Google Scholar

272. Georgel P, Radosavljevic M, Macquin C, and Bahram S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol Immunol. (2011) 48:769–75. doi: 10.1016/j.molimm.2010.12.002, PMID: 21190736

PubMed Abstract | Crossref Full Text | Google Scholar

273. Zhao Z, Wang H, Shi M, Zhu T, Pediongco T, Lim XY, et al. Francisella tularensis induces Th1 like MAIT cells conferring protection against systemic and local infection. Nat Commun. (2021) 12:4355. doi: 10.1038/s41467-021-24570-2, PMID: 34272362

PubMed Abstract | Crossref Full Text | Google Scholar

274. Riffelmacher T, Paynich Murray M, Wientjens C, Chandra S, Cedillo-Castelán V, Chou TF, et al. Divergent metabolic programmes control two populations of MAIT cells that protect the lung. Nat Cell Biol. (2023) 25:877–91. doi: 10.1038/s41556-023-01152-6, PMID: 37231163

PubMed Abstract | Crossref Full Text | Google Scholar

275. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, and Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun. (2012) 80:3256–67. doi: 10.1128/IAI.00279-12, PMID: 22778103

PubMed Abstract | Crossref Full Text | Google Scholar

276. Meermeier EW, Zheng CL, Tran JG, Soma S, Worley AH, Weiss DI, et al. Human lung-resident mucosal-associated invariant T cells are abundant, express antimicrobial proteins, and are cytokine responsive. Commun Biol. (2022) 5:1–13. doi: 10.1038/s42003-022-03823-w, PMID: 36085311

PubMed Abstract | Crossref Full Text | Google Scholar

277. Nel I, Bertrand L, Toubal A, and Lehuen A. MAIT cells, guardians of skin and mucosa? Mucosal Immunol. (2021) 14:803–14. doi: 10.1038/s41385-021-00391-w, PMID: 33753874

PubMed Abstract | Crossref Full Text | Google Scholar

278. Winchell CG, Nyquist SK, Chao MC, Maiello P, Myers AJ, Hopkins F, et al. CD8+ lymphocytes are critical for early control of tuberculosis in macaques. J Exp Med. (2023) 220:e20230707. doi: 10.1084/jem.20230707, PMID: 37843832

PubMed Abstract | Crossref Full Text | Google Scholar

279. Simonson AW, Zeppa JJ, Bucsan AN, Chao MC, Pokkali S, Hopkins F, et al. Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. J Exp Med. (2025) 222:e20241571. doi: 10.1084/jem.20241571, PMID: 39912921

PubMed Abstract | Crossref Full Text | Google Scholar

280. Cross DL, Layton ED, Yu KKQ, Smith MT, Aguilar MS, Li S, et al. MR1-restricted T cell clonotypes are associated with “resistance” to Mycobacterium tuberculosis infection. JCI Insight. (2024) 9. doi: 10.1172/jci.insight.166505, PMID: 38716731

PubMed Abstract | Crossref Full Text | Google Scholar

281. Kain D, Awad W, McElfresh GW, Cansler M, Swarbrick GM, Poa KCY, et al. Human neonatal MR1T cells have diverse TCR usage, are less cytotoxic and are unable to respond to many common childhood pathogens. BioRxiv Prepr Serv Biol. (2025) 2025:03.17.643805. doi: 10.1101/2025.03.17.643805, PMID: 40166301

PubMed Abstract | Crossref Full Text | Google Scholar

282. Gold MC, McLaren JE, Reistetter JA, Smyk-Pearson S, Ladell K, Swarbrick GM, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med. (2014) 211:1601–10. doi: 10.1084/jem.20140507, PMID: 25049333

PubMed Abstract | Crossref Full Text | Google Scholar

283. Prota G, Berloffa G, Awad W, Vacchini A, Chancellor A, Schaefer V, et al. Mitochondria regulate MR1 protein expression and produce self-metabolites that activate MR1-restricted T cells. Proc Natl Acad Sci. (2025) 122:e2418525122. doi: 10.1073/pnas.2418525122, PMID: 40354545

PubMed Abstract | Crossref Full Text | Google Scholar

284. Vacchini A, Chancellor A, Yang Q, Colombo R, Spagnuolo J, Berloffa G, et al. Nucleobase adducts bind MR1 and stimulate MR1-restricted T cells. Sci Immunol. (2024) 9:eadn0126. doi: 10.1126/sciimmunol.adn0126, PMID: 38728413

PubMed Abstract | Crossref Full Text | Google Scholar

285. Chancellor A, Constantin D, Berloffa G, Yang Q, Nosi V, Loureiro JP, et al. The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. Immunity. (2025) 58:431–447.e10. doi: 10.1016/j.immuni.2024.11.019, PMID: 39701104

PubMed Abstract | Crossref Full Text | Google Scholar

286. McWilliam HEG, Mak JYW, Awad W, Zorkau M, Cruz-Gomez S, Lim HJ, et al. Endoplasmic reticulum chaperones stabilize ligand-receptive MR1 molecules for efficient presentation of metabolite antigens. Proc Natl Acad Sci. (2020) 117:24974–85. doi: 10.1073/pnas.2011260117, PMID: 32958637

PubMed Abstract | Crossref Full Text | Google Scholar

287. McWilliam HEG, Eckle SBG, Theodossis A, Liu L, Chen Z, Wubben JM, et al. The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. Nat Immunol. (2016) 17:531–7. doi: 10.1038/ni.3416, PMID: 27043408

PubMed Abstract | Crossref Full Text | Google Scholar

288. Huang S, Gilfillan S, Kim S, Thompson B, Wang X, Sant AJ, et al. MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells. J Exp Med. (2008) 205:1201–11. doi: 10.1084/jem.20072579, PMID: 18443227

PubMed Abstract | Crossref Full Text | Google Scholar

289. Reantragoon R, Kjer-Nielsen L, Patel O, Chen Z, Illing PT, Bhati M, et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J Exp Med. (2012) 209:761–74. doi: 10.1084/jem.20112095, PMID: 22412157

PubMed Abstract | Crossref Full Text | Google Scholar

290. Keller AN, Eckle SBG, Xu W, Liu L, Hughes VA, Mak JYW, et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat Immunol. (2017) 18:402–11. doi: 10.1038/ni.3679, PMID: 28166217

PubMed Abstract | Crossref Full Text | Google Scholar

291. Kulicke CA, Swarbrick GM, Ladd NA, Cansler M, Null M, Worley A, et al. Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activation. Commun Biol. (2024) 7:1–13. doi: 10.1038/s42003-024-05912-4, PMID: 38402309

PubMed Abstract | Crossref Full Text | Google Scholar

292. Salio M, Awad W, Veerapen N, Gonzalez-Lopez C, Kulicke C, Waithe D, et al. Ligand-dependent downregulation of MR1 cell surface expression. Proc Natl Acad Sci. (2020) 117:10465–75. doi: 10.1073/pnas.2003136117, PMID: 32341160

PubMed Abstract | Crossref Full Text | Google Scholar

293. Patel O, Kjer-Nielsen L, Le Nours J, Eckle SBG, Birkinshaw R, Beddoe T, et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun. (2013) 4:2142. doi: 10.1038/ncomms3142, PMID: 23846752

PubMed Abstract | Crossref Full Text | Google Scholar

294. Krawic JR, Ladd NA, Cansler M, McMurtrey C, Devereaux J, Worley A, et al. Multiple isomers of photolumazine V bind MR1 and differentially activate MAIT cells. J Immunol. (2024) 212:933–40. doi: 10.4049/jimmunol.2300609, PMID: 38275935

PubMed Abstract | Crossref Full Text | Google Scholar

295. Chengalroyen MD, Oketade N, Worley A, Lucas M, Ramirez LN, Raphela ML, et al. Disruption of riboflavin biosynthesis in mycobacteria establishes 5-amino-6-D-ribitylaminouracil (5-A-RU) as key precursor of MAIT cell agonists [Internet. bioRxiv. (2024) 2024:.10.03.616430. doi: 10.1101/2024.10.03.616430v2

Crossref Full Text | Google Scholar

296. Ryan GJ, Hoff DR, Driver ER, Voskuil MI, Gonzalez-Juarrero M, Basaraba RJ, et al. Multiple M. tuberculosis phenotypes in mouse and Guinea pig lung tissue revealed by a dual-staining approach. PloS One. (2010) 5:e11108. doi: 10.1371/journal.pone.0011108, PMID: 20559431

PubMed Abstract | Crossref Full Text | Google Scholar

297. Borah K, Mendum TA, Hawkins ND, Ward JL, Beale MH, Larrouy-Maumus G, et al. Metabolic fluxes for nutritional flexibility of Mycobacterium tuberculosis. Mol Syst Biol. (2021) 17:e10280. doi: 10.15252/msb.202110280, PMID: 33943004

PubMed Abstract | Crossref Full Text | Google Scholar

298. Muttucumaru DGN, Roberts G, Hinds J, Stabler RA, and Parish T. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis. (2004) 84:239–46. doi: 10.1016/j.tube.2003.12.006, PMID: 15207493

PubMed Abstract | Crossref Full Text | Google Scholar

299. Voskuil MI. Mycobacterium tuberculosis gene expression during environmental conditions associated with latency. Tuberculosis. (2004) 84:138–43. doi: 10.1016/j.tube.2003.12.008, PMID: 15207483

PubMed Abstract | Crossref Full Text | Google Scholar

300. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages : Insights into the Phagosomal Environment. J Exp Med. (2003) 198:693–704. doi: 10.1084/jem.20030846, PMID: 12953091

PubMed Abstract | Crossref Full Text | Google Scholar

301. Keren I, Minami S, Rubin E, and Lewis K. Characterization and transcriptome analysis of mycobacterium tuberculosis persisters. mBio. (2011) 2. doi: 10.1128/mbio.00100-11, PMID: 21673191

PubMed Abstract | Crossref Full Text | Google Scholar

302. Eoh H, Wang Z, Layre E, Rath P, Morris R, Branch Moody D, et al. Metabolic anticipation in Mycobacterium tuberculosis. Nat Microbiol. (2017) 2:1–7. doi: 10.1038/nmicrobiol.2017.84, PMID: 28530656

PubMed Abstract | Crossref Full Text | Google Scholar

303. Osório NS, Rodrigues F, Gagneux S, Pedrosa J, Pinto-Carbó M, Castro AG, et al. Evidence for diversifying selection in a set of mycobacterium tuberculosis genes in response to antibiotic- and nonantibiotic-related pressure. Mol Biol Evol. (2013) 30:1326–36. doi: 10.1093/molbev/mst038, PMID: 23449927

PubMed Abstract | Crossref Full Text | Google Scholar

304. Pepperell CS, Casto AM, Kitchen A, Granka JM, Cornejo OE, Holmes EC, et al. The role of selection in shaping diversity of natural M. tuberculosis Popul PloS Pathog. (2013) 9:e1003543. doi: 10.1371/journal.ppat.1003543, PMID: 23966858

PubMed Abstract | Crossref Full Text | Google Scholar

305. Preciado-Llanes L, Aulicino A, Canals R, Moynihan PJ, Zhu X, Jambo N, et al. Evasion of MAIT cell recognition by the African Salmonella Typhimurium ST313 pathovar that causes invasive disease. Proc Natl Acad Sci. (2020) 117:20717–28. doi: 10.1073/pnas.2007472117, PMID: 32788367

PubMed Abstract | Crossref Full Text | Google Scholar

306. Shibata K, Shimizu T, Nakahara M, Ito E, Legoux F, Fujii S, et al. The intracellular pathogen Francisella tularensis escapes from adaptive immunity by metabolic adaptation. Life Sci Alliance. (2022) 5. doi: 10.26508/lsa.202201441, PMID: 35667686

PubMed Abstract | Crossref Full Text | Google Scholar

307. Dey RJ, Dey B, Harriff M, Canfield ET, Lewinsohn DM, and Bishai WR. Augmentation of the riboflavin-biosynthetic pathway enhances mucosa-associated invariant T (MAIT) cell activation and diminishes mycobacterium tuberculosis virulence. mBio. (2022) 13:e03865–21. doi: 10.1128/mbio.03865-21, PMID: 35164552

PubMed Abstract | Crossref Full Text | Google Scholar

308. Van Rhijn I and Moody DB. Donor unrestricted T cells: A shared human T cell response. J Immunol. (2015) 195:1927–32. doi: 10.4049/jimmunol.1500943, PMID: 26297792

PubMed Abstract | Crossref Full Text | Google Scholar

309. Vorkas CK, Levy O, Skular M, Li K, Aubé J, and Glickman MS. Efficient 5-OP-RU-induced enrichment of mucosa-associated invariant T cells in the murine lung does not enhance control of aerosol mycobacterium tuberculosis infection. Infect Immun. (2020) 89. doi: 10.1128/iai.00524-20, PMID: 33077620

PubMed Abstract | Crossref Full Text | Google Scholar

310. Sakai S, Lora NE, Kauffman KD, Dorosky DE, Oh S, Namasivayam S, et al. Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Mucosal Immunol. (2021) 14:1055–66. doi: 10.1038/s41385-021-00425-3, PMID: 34158594

PubMed Abstract | Crossref Full Text | Google Scholar

311. Wang H, Souter MNT, de Lima Moreira M, Li S, Zhou Y, Nelson AG, et al. MAIT cell plasticity enables functional adaptation that drives antibacterial immune protection. Sci Immunol. (2024) 9:eadp9841. doi: 10.1126/sciimmunol.adp9841, PMID: 39642244

PubMed Abstract | Crossref Full Text | Google Scholar

312. Rivera-Lugo R, Castillo JG, Lobanovska M, Tang E, Anaya-Sanchez A, Espich S, et al. MAIT cells induced by engineered Listeria exhibit antibacterial and antitumor activity [Internet. bioRxiv. (2025), 2025.10.13.682223. doi: 10.1101/2025.10.13.682223v1, PMID: 41280006

PubMed Abstract | Crossref Full Text | Google Scholar

313. Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol. (2016) 17:1300–11. doi: 10.1038/ni.3565, PMID: 27668799

PubMed Abstract | Crossref Full Text | Google Scholar

314. Wang H, Kjer-Nielsen L, Shi M, D’Souza C, Pediongco TJ, Cao H, et al. IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection. Sci Immunol. (2019) 4:eaaw0402. doi: 10.1126/sciimmunol.aaw0402, PMID: 31732518

PubMed Abstract | Crossref Full Text | Google Scholar

315. Wang H, D’Souza C, Lim XY, Kostenko L, Pediongco TJ, Eckle SBG, et al. MAIT cells protect against pulmonary Legionella longbeachae infection. Nat Commun. (2018) 9:3350. doi: 10.1038/s41467-018-05202-8, PMID: 30135490

PubMed Abstract | Crossref Full Text | Google Scholar

316. Kain D, McElfresh GW, Swarbrick G, Rott K, Boggy G, Walzl G, et al. BCG Vaccination at Birth Shapes the TCR Usage and Functional Profile of MR1T Cells at 9 Weeks of Age. bioRxiv. (2025), 2025–10. doi: 10.1101/2025.10.09.681353, PMID: 41279298

PubMed Abstract | Crossref Full Text | Google Scholar

317. Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, Geldenhuys H, et al. MR1-independent activation of human mucosal-associated invariant T cells by mycobacteria. J Immunol. (2019) 203:2917–27. doi: 10.4049/jimmunol.1900674, PMID: 31611259

PubMed Abstract | Crossref Full Text | Google Scholar

318. Gela A, Murphy M, Rodo M, Hadley K, Hanekom WA, Boom WH, et al. Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. eBioMedicine. (2022) 76. doi: 10.1016/j.ebiom.2022.103839, PMID: 35149285

PubMed Abstract | Crossref Full Text | Google Scholar

319. Greene JM, Dash P, Roy S, McMurtrey C, Awad W, Reed JS, et al. MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. Mucosal Immunol. (2017) 10:802–13. doi: 10.1038/mi.2016.91, PMID: 27759023

PubMed Abstract | Crossref Full Text | Google Scholar

320. Moseki RM and Chengalroyen MD. Rethinking BCG vaccine delivery for enhanced efficacy: Are two distinct routes of BCG administration better than one? hLife. (2025) 3:61–3. doi: 10.1016/j.hlife.2024.12.002

Crossref Full Text | Google Scholar

321. Shanu-Wilson J, Coe S, Evans L, Steele J, and Wrigley S. Small molecule drug metabolite synthesis and identification: why, when and how? Drug Discov Today. (2024) 29:103943. doi: 10.1016/j.drudis.2024.103943, PMID: 38452922

PubMed Abstract | Crossref Full Text | Google Scholar

322. Beck H, Härter M, Haß B, Schmeck C, and Baerfacker L. Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory. Drug Discov Today. (2022) 27:1560–74. doi: 10.1016/j.drudis.2022.02.015, PMID: 35202802

PubMed Abstract | Crossref Full Text | Google Scholar